

AUSTRALIAN PRODUCT INFORMATION - JARDIAMET empagliflozin and metformin hydrochloride film coated tablets

1 NAME OF THE MEDICINE

empagliflozin and metformin hydrochloride

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

- JARDIAMET 5 mg/500 mg contains 5 mg empagliflozin and 500 mg metformin hydrochloride
- JARDIAMET 5 mg/850 mg contains 5 mg empagliflozin and 850 mg metformin hydrochloride
- JARDIAMET 5 mg/1000 mg contains 5 mg empagliflozin and 1000 mg metformin hydrochloride
- JARDIAMET 12.5 mg/500 mg contains 12.5 mg empagliflozin and 500 mg metformin hydrochloride
- JARDIAMET 12.5 mg/850 mg contains 12.5 mg empagliflozin and 850 mg metformin hydrochloride
- JARDIAMET 12.5 mg/1000 mg contains 12.5 mg empagliflozin and 1000 mg metformin hydrochloride.

For the full list of excipients, see Section 6.1 List of excipients.

3 PHARMACEUTICAL FORM

JARDIAMET are film-coated tablets for oral administration and are available in six strengths:

JARDIAMET 5 mg/500 mg – orange yellow, oval, biconvex film-coated tablets. One side is debossed with the Boehringer Ingelheim company symbol and "S5" the other side is debossed with "500".

JARDIAMET 5 mg/850 mg * – yellowish white, oval, biconvex film-coated tablets. One side is debossed with Boehringer Ingelheim company symbol and "S5", the other side is debossed with "850".

JARDIAMET 5 mg/1000 mg – brownish yellow, oval, biconvex film-coated tablets. One side is debossed with Boehringer Ingelheim company symbol and "S5", the other side is debossed with "1000".

JARDIAMET 12.5 mg/500 mg – pale brownish purple, oval, biconvex film-coated tablets. One side is debossed with Boehringer Ingelheim company symbol and "S12", the other side is debossed with "500".

JARDIAMET 12.5 mg/850 mg * – pinkish white, oval, biconvex film-coated tablets. One side is debossed with Boehringer Ingelheim company symbol and "S12", the other side is debossed with "850".

JARDIAMET 12.5 mg/1000 mg – dark brownish purple, oval, biconvex film-coated tablets. One side is debossed with Boehringer Ingelheim company symbol and "S12", the other side is debossed with "1000".

* not currently distributed in Australia.

4 CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS

JARDIAMET is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin is appropriate (see Sections 4.2 Dose and method of administration and 5.1 Pharmacodynamic properties - Clinical trials).

Empagliflozin is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease to reduce the risk of cardiovascular death (see Section 5.1 Pharmacodynamic properties - Clinical trials).

To prevent cardiovascular deaths, empagliflozin should be used in conjunction with other measures to reduce cardiovascular risk in line with the current standard of care.

4.2 DOSE AND METHOD OF ADMINISTRATION

Life-threatening lactic acidosis can occur due to accumulation of metformin. Risk factors include renal impairment, old age and the use of high doses of metformin above 2000 mg per day.

The recommended dose is one JARDIAMET tablet twice daily.

The dosage should be individualised on the basis of the patient's current regimen, effectiveness, and tolerability. The maximum recommended daily dose of JARDIAMET is 25 mg of empagliflozin and 2000 mg of metformin.

JARDIAMET should be given with meals to reduce the gastrointestinal undesirable effects associated with metformin.

Treatment naïve patients

The recommended starting dose is 5 mg/500 mg twice daily. If additional glycaemic control is required, adjust dosing based on effectiveness and tolerability while not exceeding the maximum recommended daily dose of 25 mg empagliflozin and 2000 mg metformin.

Patients switching from separate tablets of empagliflozin and metformin

Patients switching from separate tablets of empagliflozin (10 mg or 25 mg total daily dose) and metformin to JARDIAMET, should receive the same daily dose of empagliflozin and metformin already being taken or the nearest therapeutically appropriate dose of metformin.

Patients not adequately controlled on the maximal tolerated dose of metformin alone or in combination with other products, including insulin.

The recommended starting dose of JARDIAMET should provide empagliflozin 5 mg twice daily (10 mg total daily dose) and the dose of metformin similar to the dose already being taken. In patients tolerating a total daily dose of empagliflozin 10 mg, the dose can be increased to a total daily dose of empagliflozin 25 mg.

Combination use

When JARDIAMET is used in combination with a sulfonylurea and/or insulin, a lower dose of sulfonylurea and/or insulin may be required to reduce the risk of hypoglycaemia (see Sections 4.5 Interactions with other medicines and other forms of interactions and 4.8 Adverse effects (Undesirable effects)).

Renal impairment

No dose adjustment is recommended for patients with mild renal impairment. JARDIAMET is contraindicated for use in patients with moderate or severe renal impairment (creatinine clearance <60 mL/min) (see Section 4.3 Contraindications).

Renal function should be assessed before initiation of treatment with metformin containing products and at least annually thereafter.

In patients at an increased risk of further progression of renal impairment and in the elderly, renal function should be assessed more frequently, e.g. every 3-6 months (see Section 4.4 Special warnings and precautions for use).

Elderly Patients

Patients age 75 years and older may be at an increased risk of volume depletion, therefore, JARDIAMET should be prescribed with caution in these patients. Therapeutic experience in patients aged 85 years and older is limited. Initiation of treatment in this population is not recommended (see Section 4.4 Special warnings and precautions for use – Use in the elderly).

Paediatric population

JARDIAMET is not recommended for use in children below 18 years due to lack of data on safety and efficacy.

4.3 CONTRAINDICATIONS

- Hypersensitivity to active ingredients empagliflozin and/or metformin hydrochloride or to any of the excipients
- Any type of metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis)
- Diabetic pre-coma
- Renal failure or renal dysfunction (creatinine clearance <60 mL/min), which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicaemia
- Acute conditions with the potential to alter renal function such as: dehydration, severe infection, shock, intravascular administration of iodinated contrast agents (see Section 4.4 Special warnings and precautions for use)
- Acute or chronic disease which may cause tissue hypoxia such as: cardiac or respiratory failure, recent myocardial infarction, shock, pulmonary embolism, acute significant blood loss, sepsis, gangrene, pancreatitis (see Section 4.4 Special warnings and precautions for use)
- During or immediately following surgery where insulin is essential, elective major surgery
- Hepatic impairment, acute alcohol intoxication, alcoholism (due to the metformin component)
- Lactation.

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

General

JARDIAMET should not be used in patients with type 1 diabetes (see Section 4.1 Therapeutic indications).

Diabetic ketoacidosis

JARDIAMET should not be used for the treatment of diabetic ketoacidosis.

Cases of diabetic ketoacidosis (DKA), a serious life-threatening condition requiring urgent hospitalisation, have been reported in postmarketing surveillance in patients treated with SGLT2 inhibitors, including empagliflozin. Fatal cases of ketoacidosis have been reported in patients taking empagliflozin.

Patients treated with JARDIAMET who present with signs and symptoms consistent with severe metabolic acidosis should be assessed for ketoacidosis regardless of presenting blood glucose levels as ketoacidosis associated with JARDIAMET may be present even if blood glucose levels are less than 13.8 mmol/L.

Signs and symptoms of ketoacidosis may include excessive thirst, nausea, vomiting, abdominal pain, generalised malaise, and shortness of breath. If ketoacidosis is suspected, JARDIAMET should be discontinued, the patient should be evaluated and prompt treatment should be instituted. Treatment of ketoacidosis generally requires insulin, fluid, potassium and carbohydrate replacement.

Restarting SGLT2 inhibitor treatment in patients with previous DKA while on SGLT2 inhibitor treatment is not recommended, unless another clear precipitating factor is identified and resolved.

Before initiating JARDIAMET, consider factors in the patient history that may predispose to ketoacidosis.

Factors that predispose patients to ketoacidosis include a low carbohydrate diet, dehydration, acute illness, surgery (see Section Surgery), a previous ketoacidosis, insulin deficiency from any cause (including insulin pump failure, history of pancreatitis, or pancreatic surgery), malnourishment/reduced caloric intake or increased insulin requirements due to infections, and alcohol abuse. JARDIAMET should be used with caution in these patients. Consider monitoring for ketoacidosis and temporarily discontinuing JARDIAMET in clinical situations known to predispose to ketoacidosis. When reducing the insulin dose in patients requiring insulin, caution should be taken (see Section 4.2 Dose and method of administration).

Lactic acidosis

Lactic acidosis is a rare but serious (high mortality in the absence of prompt treatment), metabolic complication that can occur due to metformin accumulation. Reported cases of lactic acidosis in patients on metformin have occurred primarily in diabetic patients with significant renal failure. The incidence of lactic acidosis can and should be reduced by assessing other associated risk factors such as poorly controlled diabetes, ketosis, prolonged fasting, excessive alcohol intake, hepatic impairment and any condition associated with hypoxia.

Diagnosis

The risk of lactic acidosis must be considered in the event of non-specific signs such as muscle cramps with digestive disorders such as abdominal pain and severe asthenia.

Lactic acidosis is characterised by acidotic dyspnea, abdominal pain and hypothermia followed by coma. Diagnostic laboratory findings are decreased blood pH, plasma lactate levels above 5 mmol/L, and an increased anion gap and lactate/pyruvate ratio. If metabolic acidosis is suspected, metformin should be discontinued and the patient should be hospitalised immediately (see Section 4.9 Overdose).

Cardiac function

Patients with heart failure are more at risk of hypoxia and renal insufficiency. In patients with stable chronic heart failure, JARDIAMET may be used with a regular monitoring of cardiac and renal function.

For patients with acute and unstable heart failure, JARDIAMET is contraindicated due to the metformin component (see Section 4.3 Contraindications).

Use in patients at risk for volume depletion

Based on the mode of action of SGLT2 inhibitors, osmotic diuresis accompanying therapeutic glucosuria may lead to a modest decrease in blood pressure. Therefore, caution should be exercised in patients for whom an empagliflozin-induced drop in blood pressure could pose a risk, such as patients with known cardiovascular disease, patients on anti-hypertensive therapy with a history of hypotension or patients aged 75 years and older.

In case of conditions that may lead to fluid loss (e.g. gastrointestinal illness), careful monitoring of volume status (e.g. physical examination, blood pressure measurements, laboratory tests including haematocrit) and electrolytes is recommended for patients receiving empagliflozin. Temporary interruption of treatment with JARDIAMET should be considered until the fluid loss is corrected.

Urosepsis and Pyelonephritis

There have been postmarketing reports of serious urinary tract infections including urosepsis and pyelonephritis requiring hospitalisation in patients receiving SGLT2 inhibitors, including empagliflozin. Treatment with SGLT2 inhibitors increases the risk for urinary tract infections. Evaluate patients for signs and symptoms of urinary tract infections and treat promptly, if indicated (see Section 4.8 Adverse effects (Undesirable effects)).

Discontinuation of JARDIAMET may be considered in cases of recurrent urinary tract infections.

Genital infections including life threatening necrotising fasciitis

Postmarketing cases of necrotising fasciitis of the perineum (also known as Fournier's gangrene), a rare, but serious and life-threatening necrotising infection, have been reported in female and male patients with diabetes mellitus treated with SGLT2 inhibitors, including empagliflozin. Serious outcomes have included hospitalisation, multiple surgeries, and death.

Patients treated with JARDIAMET who present with pain or tenderness, erythema, swelling in the genital or perineal area, fever, malaise should be evaluated for necrotising fasciitis. If suspected, JARDIAMET should be discontinued and prompt treatment should be instituted (including broad-spectrum antibiotics and surgical debridement if necessary).

Lower limb amputations

An increase in cases of lower limb amputation (primarily of the toe) has been observed in a long-term clinical study with another SGLT2 inhibitor. The medicine in that study is not empagliflozin. However, it is unknown whether this constitutes a class effect. In a pooled safety analysis of 12,620 patients with T2DM the frequency of patients with lower limb amputations was similar between empagliflozin and placebo. In the largest placebo-controlled trial in 7020 patients (EMPA-REG OUTCOME trial), in which 88% of all the cases of amputations were reported, lower limb amputations occurred in 1.8% of patients treated with empagliflozin 10 mg, in 2.0% of patients treated with empagliflozin 25 mg, and in 1.8% of patients in the placebo arm. It is important to regularly examine the feet and counsel all diabetic patients on routine preventative footcare.

Combination with glucagon like peptide (GLP-1) analogues

Empagliflozin has not been studied in combination with glucagon like peptide 1 (GLP-1) analogues.

Administration of iodinated contrast agent

The intravascular administration of iodinated contrast materials in radiologic studies can lead to renal failure. This may induce metformin accumulation and may expose to lactic acidosis. Therefore, JARDIAMET must be discontinued either 48 hours before the test when renal function is known to be impaired or from the time of the test when renal function is known to be normal. JARDIAMET may not be reinstated until 48 hours afterwards, and only after renal function has been re-evaluated and found to be normal (see Section 4.5 Interactions with other medicines and other forms of interactions).

Surgery

Treatment with JARDIAMET should be ceased at least 48 hours prior to major surgery (see Sections Diabetic ketoacidosis and Lactic acidosis). An increase in other glucose lowering agents may be required during this time.

Patients scheduled for non-urgent surgery who have not ceased JARDIAMET should be assessed and consideration should be given to postponing the procedure.

Treatment with JARDIAMET may be restarted not earlier than 48 hours following surgery once the patient's condition has stabilised, oral intake is normal and only after renal function has been re-evaluated and found to be normal.

Vitamin B12 levels

In controlled clinical trials of metformin of 29 weeks duration, a decrease to subnormal levels of previously normal serum Vitamin B12 levels, without clinical manifestations, was observed in approximately 7% of patients. Such decrease, possibly due to interference with B12 absorption from the B12-intrinsic factor complex, is, however, very rarely associated with anaemia and appears to be rapidly reversible with discontinuation of metformin or Vitamin B12 supplementation. Measurement of haematologic parameters on an annual basis is advised in patients on JARDIAMET and any apparent abnormalities should be appropriately investigated and managed. Certain individuals (those with inadequate Vitamin B12 or calcium intake or absorption) appear to be predisposed to developing subnormal Vitamin B12 levels. In these patients, routine serum Vitamin B12 measurements at two- to three-year intervals may be useful.

Use in patients with renal impairment

Due to the mechanism of action, decreased renal function will result in reduced efficacy of empagliflozin.

As metformin hydrochloride is excreted by the kidney, serum creatinine levels should be determined before initiating treatment and regularly thereafter:

- at least annually in patients with normal renal function
- at least two to four times a year in patients with serum creatinine levels at the upper limit of normal and in elderly subjects.

Decreased renal function in elderly subjects is frequent and asymptomatic (see Section 5.2 Pharmacokinetic properties - Pharmacokinetics in special patient groups – Elderly). Special caution should be exercised in situations where renal function may become impaired, for example when initiating antihypertensive therapy or diuretic therapy and when starting therapy with a non-steroidal anti-inflammatory drug (NSAID).

In these cases, it is also recommended to check renal function before initiating treatment with JARDIAMET.

Use in the elderly

Patients aged 75 years and older may be at an increased risk of volume depletion, therefore, JARDIAMET should be prescribed with caution in these patients (see Section 4.8 Adverse effects (Undesirable effects)). Therapeutic experience in patients aged 85 years and older is limited. Initiation of treatment in this population is not recommended.

As metformin is excreted by the kidney, JARDIAMET should be used with caution as age increases. Monitoring of renal function is necessary to aid in prevention of metformin-associated lactic acidosis, particularly in elderly patients.

Paediatric Use

Safety and effectiveness of JARDIAMET in paediatric patients under 18 years have not been established.

Effects on laboratory tests

Urine will test positive for glucose while patients are taking JARDIAMET due to the nature of the mechanism of action of the SGLT2 inhibitors (see Section 5.1 Pharmacodynamic properties).

Interference with 1,5-anhydroglucitol (1,5-AG) assay

Monitoring glycemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control.

4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

General

Co-administration of multiple doses of empagliflozin (50 mg once daily) and metformin hydrochloride (1000 mg twice daily) did not meaningfully alter the pharmacokinetics of either empagliflozin or metformin in healthy volunteers.

Pharmacokinetic drug-drug interaction studies with JARDIAMET have not been performed; however, such studies have been conducted with empagliflozin and metformin alone.

Empagliflozin

Pharmacodynamic Interactions

Diuretics

Empagliflozin may add to the diuretic effect of thiazide and loop diuretics and may increase the risk of dehydration and hypotension.

Insulin and insulin secretagogues

Insulin and insulin secretagogues, such as sulfonylureas, may increase the risk of hypoglycaemia. Therefore, a lower dose of insulin or an insulin secretagogue may be required to reduce the risk of hypoglycaemia when used in combination with empagliflozin (see Sections 4.2 Dose and method of administration and 4.8 Adverse Effects (Undesirable effects)).

Pharmacokinetic Interactions

In vitro assessment of drug interactions

Empagliflozin does not inhibit, inactivate, or induce CYP450 isoforms. *In vitro* data suggest that the primary route of metabolism of empagliflozin in humans is glucuronidation by the uridine 5'-diphospho-glucuronosyltransferases UGT1A3, UGT1A8, UGT1A9, and UGT2B7. Empagliflozin does not notably inhibit UGT1A1, UGT1A3, UGT1A8, UGT1A9, or UGT2B7. At therapeutic doses, the potential for empagliflozin to reversibly inhibit or inactivate the major CYP450 and UGT isoforms is remote. Drug-drug interactions involving the major CYP450 and UGT isoforms with empagliflozin and concomitantly administered substrates of these enzymes are therefore considered unlikely.

Empagliflozin is a substrate for P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), but it does not inhibit these efflux transporters at therapeutic doses. Based on *in vitro* studies, empagliflozin is considered unlikely to cause interactions with drugs that are P-gp substrates. Empagliflozin is a substrate of the human uptake transporters OAT3, OATP1B1, and OATP1B3, but not OAT1 and OCT2. Empagliflozin does not inhibit any of these human uptake transporters at clinically relevant plasma concentrations and, as such, drug-drug interactions with substrates of these uptake transporters are considered unlikely.

In vivo assessment of drug interactions

No clinically meaningful pharmacokinetic interactions were observed when empagliflozin was co-administered with other commonly used medicinal products. Based on results of pharmacokinetic studies no dose adjustment of empagliflozin is recommended when co-administered with commonly prescribed medicinal products.

Empagliflozin pharmacokinetics were similar with and without co-administration of glimepiride, pioglitazone, sitagliptin, linagliptin, warfarin, verapamil, ramipril, simvastatin, in healthy volunteers and with or without co-administration of torasemide and hydrochlorothiazide in patients with T2DM. Increases in overall exposure (AUC) of empagliflozin were seen following co-administration with gemfibrozil (59%), rifampicin (35%), or probenecid (53%). These changes were not considered to be clinically meaningful.

Empagliflozin had no clinically relevant effect on the pharmacokinetics of glimepiride, pioglitazone, sitagliptin, linagliptin, warfarin, digoxin, ramipril, simvastatin, hydrochlorothiazide, torasemide and oral contraceptives when co-administered in healthy volunteers.

Metformin hydrochloride

Contraindicated combinations

Iodinated contrast materials

JARDIAMET must be discontinued either 48 hours before the test when renal function is known to be impaired, or from the time of the test when renal function is known to be normal (see Sections 4.3 Contraindications and 4.4 Special warnings and precautions for use - Administration of iodinated contrast materials).

Inadvisable combinations

Alcohol

There is increased risk of lactic acidosis in acute alcohol intoxication (particularly in the case of fasting, malnutrition or hepatic impairment) due to the metformin component of JARDIAMET (see Section 4.4 Special warnings and precautions for use – Lactic acidosis). Consumption of alcohol and medicinal products containing alcohol should be avoided. Alcohol may make the signs of hypoglycaemia less clear, and delayed hypoglycaemia can occur. The CNS depressant effects of alcohol plus hypoglycaemia can make driving or the operation of dangerous machinery much more hazardous.

Combinations requiring precautions for use

Medicinal products with intrinsic hyperglycaemic activity e.g. glucocorticoids and tetracosactides (systemic and local routes), beta-2-agonists, danazol, chlorpromazine at high dosages of 100 mg per day and diuretics

More frequent blood glucose monitoring may be required, especially at the beginning of treatment. If necessary, adjust the metformin dosage during therapy with the respective medicinal product and upon discontinuation.

Diuretics, especially loop diuretics

May increase the risk of lactic acidosis due to their potential to decrease renal function.

ACE-inhibitors

ACE-inhibitors may decrease the blood glucose levels. Therefore, dose adjustment of JARDIAMET may be necessary when such medicinal products are added or discontinued.

Calcium channel blockers

Calcium channel blockers may affect glucose control in diabetic patients; regular monitoring of glycaemic control is recommended.

Beta-blockers

Co-administration of metformin and beta-blockers may result in a potentiation of the anti-hyperglycaemic action. In addition, some of the premonitory signs of hypoglycaemia, in particular tachycardia, may be masked. Monitoring of blood glucose should be undertaken during dosage adjustment of either agent.

Cimetidine

Reduced clearance of metformin has been reported during cimetidine therapy, so a dose reduction should be considered.

Anticoagulants

Metformin increases the elimination rate of vitamin K antagonists. Consequently, the prothrombin time should be closely monitored in patients in whom metformin and vitamin K antagonists are being co-administered. Cessation of metformin in patients receiving vitamin K antagonists can cause marked increases in the prothrombin time.

Nifedipine

A single-dose, metformin-nifedipine drug interaction study in normal healthy volunteers demonstrated that co-administration of metformin and nifedipine increased plasma metformin C_{max} and AUC by 20% and 9%, respectively, and increased the amount of metformin excreted in the urine. T_{max} and half-life of metformin were unaffected. Nifedipine appears to enhance the absorption of metformin. Metformin had minimal effects on the pharmacokinetics of nifedipine.

Organic cation transporters (OCT)

Metformin is a substrate of both transporters OCT1 and OCT2.

Co-administration of metformin with:

- Substrates/inhibitors of OCT1 (such as verapamil) may reduce efficacy of metformin.
- Inducers of OCT1 (such as rifampicin) may increase gastrointestinal absorption and efficacy.
- Substrates/inhibitors of OCT2 (such as cimetidine, dolutegravir, crizotinib, olaparib, daclatasvir, vandetanib) may decrease the renal elimination of metformin and thus lead to an increase in metformin plasma concentration.

Therefore, caution is advised when these drugs are co-administered with metformin and a dose adjustment may be considered, particularly in patients with renal impairment.

4.6 FERTILITY, PREGNANCY AND LACTATION

Effects on Fertility

No studies on the effect on human fertility have been conducted with JARDIAMET or its individual components.

Nonclinical studies in animals with the individual components do not indicate direct or indirect harmful effects with respect to fertility.

Empagliflozin

Studies in rats at doses up to 700 mg/kg/day, do not indicate direct or indirect harmful effects with respect to fertility. In female rats this dose was 90- and 155-fold the systemic AUC exposure anticipated with a human dose of 10 and 25 mg.

Metformin hydrochloride

Fertility of male or female rats was unaffected by metformin when administered at doses up to 600 mg/kg/day, which is approximately 2 times the maximum recommended human daily dose based on body surface area comparisons.

Use in Pregnancy (Category D)

There are limited data from the use of JARDIAMET or its individual components in pregnant women.

It is recommended to avoid the use of JARDIAMET during pregnancy unless clearly needed.

A study in pregnant rats did not reveal teratogenicity or other adverse effects on embryofetal development with co-administration of empagliflozin and metformin at oral doses up to 100/200 mg/kg/day, yielding exposures of approximately 35- and 14-times the clinical AUC exposure of empagliflozin associated with the 5 and 12.5 mg twice daily doses, respectively, and 4-times the clinical AUC exposure of metformin associated with the 1000 mg twice daily dose. At a dose of 300/600 mg/kg/day, associated with 49-times the exposure to empagliflozin and 8-times the exposure to metformin in humans at the maximum recommended dose, teratogenicity attributable to the metformin component was observed.

Empagliflozin

Empagliflozin administered during the period of organogenesis was not teratogenic at doses up to 300 mg/kg in the rat or rabbit, which corresponds to approximately 48- and 122-times or 128- and 325-times the clinical dose of empagliflozin based on AUC exposure associated with the 12.5 mg and 5 mg twice daily doses, respectively. Doses of empagliflozin causing maternal toxicity in the rat also caused the malformation of bent limb bones at exposures approximately 155- and 393-times the clinical dose associated with the 12.5 mg and 5 mg twice daily doses, respectively. Maternally toxic doses in the rabbit also caused increased embryofetal loss at doses approximately 139- and 353-times the clinical dose associated with the 12.5 mg and 5 mg twice daily doses, respectively.

Empagliflozin administered to female rats from gestation day 6 to lactation day 20 resulted in reduced weight gain in offspring at ≥ 30 mg/kg/day yielding maternal exposures approximately 4- and 11-times those in humans associated with 12.5 mg and 5 mg twice daily doses, respectively.

Specialised studies in rats with other members of the pharmacological class have shown toxicity to the developing kidney in the time period corresponding to the second and third

trimesters of human pregnancy. Similar effects have been seen for empagliflozin at approximately 11-times the clinical dose of empagliflozin based on AUC exposure associated with the 12.5 mg twice daily dose. These findings were absent after a 13 week drug-free recovery period.

Metformin hydrochloride

Metformin was not teratogenic in rats at a dose of 200 mg/kg/day associated with a systemic exposure 4 times that in patients at the maximum recommended human dose (2000 mg metformin per day). At higher doses (500 and 1000 mg/kg/day, associated with 11 and 23 times the clinical exposure at the MRHD), teratogenicity of metformin was observed in the rat which was mostly evident as an increase in the incidence of skeletal malformations.

Use in Lactation

Metformin is excreted into human breast milk. No adverse effects were observed in breastfed newborns/infants. It is unknown whether empagliflozin is excreted in human milk.

Available nonclinical data in animals have shown excretion of empagliflozin in milk. Reduced body weight was observed in rats exposed to empagliflozin *in utero* and through the consumption of maternal milk (see Use in Pregnancy). Adverse effects on renal development have been observed in juvenile rats treated with other members of this pharmacological class. Similar effects were seen with empagliflozin but the findings were absent after a 13 week drug-free recovery. A risk to human newborns/infants cannot be excluded. It is recommended to discontinue breast feeding during treatment with JARDIAMET.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

No studies on the effects on the ability to drive and use machines have been performed.

4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

Reporting suspected adverse effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at <http://www.tga.gov.au/reporting-problems>.

Adverse Reactions in Clinical Trials

A total of 12,245 patients with type 2 diabetes were treated in clinical studies to evaluate the safety of empagliflozin plus metformin, of which 8199 patients were treated with empagliflozin plus metformin, either alone, or in addition to a sulfonylurea, pioglitazone, DPP4 inhibitors, or insulin. In these trials 2910 patients received treatment with empagliflozin 10 mg plus metformin and 3699 patients treatment with empagliflozin 25 mg plus metformin for at least 24 weeks and 2151 or 2807 patients for at least 76 weeks.

The overall safety profile of empagliflozin plus metformin for patients enrolled in the EMPA-REG OUTCOME study was comparable to the previously known safety profile.

Placebo controlled double-blind trials of 18 to 24 weeks of exposure included 3456 patients, of which 1271 were treated with empagliflozin 10 mg plus metformin and 1259 with empagliflozin 25 mg plus metformin.

The most frequently reported adverse event in clinical trials was hypoglycaemia, which depended on the type of background therapy used in the respective studies (Table 1).

No additional side effects were identified in clinical trials with empagliflozin plus metformin compared to the side effects of the single components.

Tabulated list of adverse reactions

The adverse reactions are listed by absolute frequency. Frequencies are defined as very common ($\geq 1/10$), common ($\geq 1/100$ to $< 1/10$), uncommon ($\geq 1/1,000$ to $< 1/100$), rare ($\geq 1/10,000$ to $< 1/1,000$), or very rare ($< 1/10,000$), and not known (cannot be estimated from the available data).

Table 1 Adverse reactions reported in placebo-controlled studies

System organ class	Very common	Common	Uncommon	Very rare
Infections and infestations		Vaginal moniliasis, vulvovaginitis, balanitis and other genital infection ^{1,2} Urinary tract infection ^{1,2}		
Metabolism and nutrition disorders	Hypoglycaemia (when used with sulfonylurea or insulin) ¹			Lactic acidosis ³ Vitamin B12 deficiency ^{3,4}
Nervous system disorders		Taste disturbance ³		
Vascular disorders			Volume depletion ^{1,2}	
Gastrointestinal disorders	Gastrointestinal symptoms ^{3,5}			
Hepatobiliary disorders				Liver function tests abnormalities ³ Hepatitis ³
Skin and subcutaneous tissue disorders		Pruritus ^{2,3} (generalised)		Erythema ³ Urticaria ³
Renal and urinary disorders		Increased urination ^{1,2}	Dysuria ²	
General disorders and administration site conditions		Thirst ²		
Investigations		Serum lipids increased ^{1,2}	Glomerular filtration rate decreased ¹ Blood creatinine increased ¹ Haematocrit increased ^{1,2}	

¹ See subsections below for additional information

² Identified adverse reactions of empagliflozin monotherapy

³ Identified adverse reactions of metformin monotherapy

⁴ Long-term treatment with metformin has been associated with a decrease in vitamin B12 absorption which may very rarely result in clinically significant vitamin B12 deficiency (e.g. megaloblastic anaemia) (see Section 4.4 Special warnings and precautions for use – Vitamin B12 levels)

⁵ Gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite occur most frequently during initiation of therapy and resolve spontaneously in most cases.

Postmarketing experience

The following postmarketing case reports have been reported during post-approval use of empagliflozin. Because these cases are reported voluntarily from a population of an unknown size, it is not always possible to reliably estimate their frequency.

Metabolism and nutrition disorders - Ketoacidosis

Infections and infestations - Pyelonephritis, urosepsis, necrotising fasciitis of the perineum (Fournier's gangrene)

Immune system disorders - Allergic skin reactions (e.g. rash, urticaria), angioedema.

Hypoglycaemia

The frequency of hypoglycaemia depended on the background therapy in the respective studies and was similar to placebo for empagliflozin as add-on to metformin and as add-on to pioglitazone +/- metformin, and as add-on with linagliptin + metformin. The frequency of patients with hypoglycaemia was increased in patients treated with empagliflozin compared to placebo when given as add-on to metformin plus sulfonylurea, and as add-on to insulin +/- metformin and +/- sulfonylurea. (see Section 4.2 Dose and method of administration, Table 2 below).

Major hypoglycaemia (events requiring assistance)

The overall frequency of patients with major hypoglycaemic events was low (<1%) and similar for empagliflozin and placebo on a background of metformin. The frequency of major hypoglycaemia depended on the background therapy in the respective studies (see Section 4.2 Dose and method of administration; Table 2 below).

Table 2 Frequency of patients with confirmed hypoglycaemic events per trial and indication (1245.19, 1245.23_(met), 1245.23_(met+SU), 1245.33, 1245.49, 1276.1,1276.10, 1276.9 and 1245.25 – Treated Set¹)

Treatment group	Placebo	Empagliflozin 10 mg	Empagliflozin 25 mg
In combination with metformin (1245.23_(met)) (24 weeks)			
N	206	217	214
Overall confirmed (%)	0.5%	1.8%	1.4%
Major (%)	0%	0%	0%
In Combination with Metformin + Sulfonylurea (1245.23_(met + SU)) (24 weeks)			
N	225	224	217
Overall confirmed (%)	8.4%	16.1%	11.5%
Major (%)	0%	0%	0%
In Combination with Pioglitazone +/- Metformin (1245.19) (24 weeks)			
N	165	165	168
Overall confirmed (%)	1.8%	1.2%	2.4%
Major (%)	0%	0%	0%
In Combination with Basal Insulin +/- Metformin (1245.33) (18 weeks² / 78 weeks)			
N	170	169	155
Overall confirmed (%)	20.6% / 35.3%	19.5% / 36.1%	28.4% / 36.1%
Major (%)	0% / 0%	0% / 0%	1.3% / 1.3%
In Combination with MDI Insulin +/-Metformin (1245.49) (18 weeks² / 52 weeks)			
N	188	186	189
Overall confirmed (%)	37.2% / 58.0%	39.8% / 51.1%	41.3% / 57.7%
Major (%)	0.5% / 1.6%	0.5% / 1.6%	0.5% / 0.5%

Treatment group	Placebo	Empagliflozin 10 mg	Empagliflozin 25 mg
Empagliflozin bid versus qd as add on to metformin (1276.10) (16 weeks)			
	Placebo	Empa 10 mg	Empa 25 mg
N	107	439	437
Overall confirmed (%)	0.9%	0.5%	0.2%
Major (%)	0%	0%	0%
In Combination with metformin in drug-naïve patients (1276.1³) (24 weeks)			
	Met 500/1000 mg bid	Empa 10/25 mg qd	Empa (5/12.5 mg) + Met (500/1000 mg) bid
N	341	339	680
Overall confirmed (%)	0.6%	0.6%	1.0%
Major (%)	0%	0%	0%
In Combination with metformin and linagliptin (1275.9) (24 weeks)⁴			
N	110	112	110
Overall confirmed (%)	0.9%	0.0%	2.7%
Major (%)	0%	0%	0.9%
EMPA-REG OUTCOME (1245.25)			
	Placebo	Empa 10 mg	Empa 25 mg
N	2333	2345	2342
Overall confirmed (%)	27.9%	28%	27.6%
Major (%)	1.5%	1.4%	1.3%

Confirmed: blood glucose \leq 3.9mmol/L or required assistance; Major: required assistance

MDI = multiple daily injections; qd = once daily ; bid = Twice daily

¹ i.e. patients who received at least one dose of study drug

²The dose of insulin as background medication was to be stable for the first 18 weeks

³ Eight treatment arms: 4 combination treatments of empagliflozin (5 mg or 12.5 mg bid) and metformin (500 or 1000 mg bid) and treatment with the individual components of empagliflozin (10 mg or 25 mg qd) or metformin (500 mg or 1000 mg bid).

⁴ This was a fixed-dose combination of empagliflozin with linagliptin 5 mg with a background treatment with metformin.

Urinary tract infection

The overall frequency of urinary tract infection adverse events was higher in patients treated with empagliflozin 10 mg plus metformin (8.8%) as compared to empagliflozin 25 mg plus metformin (6.6%) or placebo plus metformin (7.8%). Similar to placebo, urinary tract infection was reported more frequently for empagliflozin plus metformin in patients with a history of chronic or recurrent urinary tract infections. The intensity of urinary tract infections was similar to placebo. Urinary tract infection events were reported more frequently for empagliflozin 10 mg plus metformin compared with placebo in female patients, but not for empagliflozin 25 mg plus metformin. The frequencies of urinary tract infections were low for male patients and were balanced across treatment groups.

Vaginal moniliasis, vulvovaginitis, balanitis and other genital infection

Vaginal moniliasis, vulvovaginitis, balanitis and other genital infections were reported more frequently for empagliflozin 10 mg plus metformin (4.0%) and empagliflozin 25 mg plus metformin (3.9%) compared to placebo plus metformin (1.3%), and were reported more frequently for empagliflozin plus metformin compared to placebo in female patients. The difference in frequency was less pronounced in male patients. Genital tract infections were mild and moderate in intensity, none was severe in intensity.

Increased urination

As expected via its mechanism of action, increased urination (as assessed by preferred term search including pollakiuria, polyuria, nocturia) was observed at higher frequencies in patients treated with empagliflozin 10 mg plus metformin (3.0%) and empagliflozin 25 mg plus metformin (2.9%) compared to placebo plus metformin (1.4%). Increased urination was

mostly mild or moderate in intensity. The frequency of reported nocturia was comparable between placebo and empagliflozin, both on a background of metformin (<1%).

Volume depletion

The overall frequency of volume depletion (including the predefined terms blood pressure (ambulatory) decreased, blood pressure systolic decreased, dehydration, hypotension, hypovolaemia, orthostatic hypotension, and syncope) was low and comparable to placebo (empagliflozin 10 mg plus metformin (0.6%), empagliflozin 25 mg plus metformin (0.3%) and placebo plus metformin (0.1%)). The effect of empagliflozin on urinary glucose excretion is associated with osmotic diuresis, which could affect the hydration status of patients age 75 years and older. In patients ≥ 75 years of age volume depletion events have been reported in a single patient treated with empagliflozin 25 mg plus metformin.

Blood creatinine increased and glomerular filtration rate decreased

The overall frequency of patients with increased blood creatinine and decreased glomerular filtration rate was similar between empagliflozin and placebo as add-on to metformin (blood creatinine increased: empagliflozin 10 mg 0.5%, empagliflozin 25 mg 0.1%, placebo 0.4%; glomerular filtration rate decreased: empagliflozin 10 mg 0.1%, empagliflozin 25 mg 0%, placebo 0.2%).

In these placebo-controlled, double-blind studies up to 24 weeks, initial transient increases in creatinine (mean change from baseline after 12 weeks: empagliflozin 10 mg 0.001 mmol/L, empagliflozin 25 mg 0.001 mmol/L) and initial transient decreases in estimated glomerular filtration rates (mean change from baseline after 12 weeks: empagliflozin 10 mg -1.46 mL/min/1.73m², empagliflozin 25 mg -2.05 mL/min/1.73m²) have been observed. In the long term studies, these changes were generally reversible during continuous treatment or after drug discontinuation (see Section 5.1 Pharmacodynamic properties - Clinical Trials Figure 4 for the eGFR course in the EMPA-REG OUTCOME study).

Laboratory parameters

Haematocrit increased

In a pooled safety analysis of all trials with metformin background treatment, mean changes from baseline in haematocrit were 3.6% and 4.0% for empagliflozin 10 mg and 25 mg, respectively, compared to 0% for placebo. In the EMPA-REG OUTCOME study, haematocrit values returned towards baseline values after a follow-up period of 30 days after treatment stop.

Serum lipids increased

In a pooled safety analysis of all trials with metformin background treatment, mean percent increases from baseline for empagliflozin 10 mg and 25 mg versus placebo, respectively, were total cholesterol 5.0% and 5.2% versus 3.7%; HDL-cholesterol 4.6% and 2.7% versus -0.5%; LDL-cholesterol 9.1% and 8.7% versus 7.8%; triglycerides 5.4% and 10.8% versus 12.1%.

4.9 OVERDOSE

For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

Symptoms

Empagliflozin

During controlled clinical trials in healthy subjects, single doses of up to 800 mg empagliflozin, equivalent to 32 times the maximum recommended daily dose, were well tolerated. There is no experience with doses above 800 mg in humans.

Metformin hydrochloride

Hypoglycaemia has not been seen with metformin hydrochloride doses of up to 85 g, although lactic acidosis has occurred in such circumstances. High overdose of metformin hydrochloride or concomitant risks may lead to lactic acidosis. Lactic acidosis is a medical emergency and must be treated in hospital.

Therapy

In the event of an overdose, supportive treatment should be initiated as appropriate to the patient's clinical status. The most effective method to remove lactate and metformin hydrochloride is haemodialysis whereas removal of empagliflozin by haemodialysis has not been studied.

5 PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Pharmacotherapeutic group: Combinations of oral blood glucose lowering drugs, ATC code: A10BD20.

Mechanism of action

Empagliflozin

Empagliflozin is a reversible competitive inhibitor of SGLT2 with an IC_{50} of 1.3 nM. It has a 5000-fold selectivity over human SGLT1 (IC_{50} of 6278 nM), responsible for glucose absorption in the gut.

SGLT2 is highly expressed in the kidney, whereas expression in other tissues is absent or very low. It is responsible as the predominant transporter for re-absorption of glucose from the glomerular filtrate back into the circulation. In patients with type 2 diabetes mellitus (T2DM) and hyperglycaemia a higher amount of glucose is filtered and reabsorbed.

Empagliflozin improves glycaemic control in patients with T2DM by reducing renal glucose re-absorption. The amount of glucose removed by the kidney through this glucuretic mechanism is dependent upon the blood glucose concentration and glomerular filtration rate (GFR). Through inhibition of SGLT2 in patients with T2DM and hyperglycaemia, excess glucose is excreted in the urine.

In patients with T2DM, urinary glucose excretion increased immediately following the first dose of empagliflozin and is continuous over the 24 hour dosing interval. Increased urinary glucose excretion was maintained at the end of 4-week treatment period, averaging approximately 78 g/day with 25 mg empagliflozin once daily. Increased urinary glucose excretion resulted in an immediate reduction in plasma glucose levels in patients with T2DM.

Empagliflozin improves both fasting and post-prandial plasma glucose levels.

The insulin independent mechanism of action of empagliflozin contributes to a low risk of hypoglycaemia.

The effect of empagliflozin in lowering blood glucose is independent of beta cell function and insulin pathway. Improvement of surrogate markers of beta cell function including Homeostasis Model Assessment- β (HOMA- β) and proinsulin to insulin ratio were noted. In addition urinary glucose excretion triggers calorie loss, associated with body fat loss and body weight reduction.

The glucosuria observed with empagliflozin is accompanied by mild diuresis which may contribute to sustained and moderate reduction of blood pressure (BP).

Metformin hydrochloride

Metformin hydrochloride is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycaemia.

Metformin hydrochloride may act via 3 mechanisms:

- 1) reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis
- 2) in muscle, by increasing insulin sensitivity, improving peripheral glucose uptake and utilisation
- 3) and delay of intestinal glucose absorption.

Metformin hydrochloride stimulates intracellular glycogen synthesis by acting on glycogen synthase.

Metformin hydrochloride increases the transport capacity of all types of membrane glucose transporters (GLUTs) known to date.

In humans, independently of its action on glycaemia, metformin hydrochloride has favourable effects on lipid metabolism. This has been shown at therapeutic doses in controlled, medium or long-term clinical studies: metformin hydrochloride reduces total cholesterol, LDL cholesterol and triglyceride levels.

Clinical trials

A total of 10,224 patients with type 2 diabetes were treated in 9 double-blind, placebo or active-controlled clinical studies, of at least 24 weeks duration, of which 2947 patients received empagliflozin 10 mg and 3703 received empagliflozin 25 mg as add-on to metformin therapy.

Treatment with empagliflozin in combination with metformin with or without other background (pioglitazone, sulfonylurea, DPP-4 inhibitors, and insulin) led to clinically relevant improvements in HbA1c, fasting plasma glucose (FPG), body weight, systolic and diastolic blood pressure (BP). Administration of empagliflozin 25 mg resulted in a higher proportion of patients achieving HbA1c goal of <7% and fewer patients needing glycaemic rescue compared to empagliflozin 10 mg and placebo. There was a clinically meaningful improvement in HbA1c in all subgroups of gender, race, geographic region, time since diagnosis of type 2 diabetes mellitus (T2DM) and body mass index (BMI). In patients aged 75 years and older, numerically lower reductions in HbA1c were observed with empagliflozin treatment. Higher baseline HbA1c was associated with a greater reduction in HbA1c. Empagliflozin in combination with metformin in drug-naïve patients led to clinically meaningful reductions in HbA1c, FPG, body weight and BP.

Empagliflozin as add on to metformin therapy

A double-blind, placebo-controlled study of 24 weeks duration was conducted to evaluate the efficacy and safety of empagliflozin in patients not sufficiently treated with metformin.

Treatment with empagliflozin resulted in statistically significant improvements in HbA1c and body weight, and clinically meaningful reductions in FPG and BP compared to placebo (Table 3).

In the double-blind placebo-controlled extension of this study, reductions of HbA1c (change from baseline of -0.62% for empagliflozin 10 mg, -0.74% for empagliflozin 25 mg and -0.01% for placebo), body weight (change from baseline of -2.39 kg for empagliflozin 10 mg, -2.65 kg for empagliflozin 25 mg and -0.46 kg for placebo) and BP (systolic BP: change from baseline of -5.2 mmHg for empagliflozin 10 mg, -4.5 mmHg for empagliflozin 25 mg and -0.8 mmHg for placebo, diastolic BP: change from baseline of -2.5 mmHg for empagliflozin 10 mg, -1.9 mmHg for empagliflozin 25 mg and -0.5 mmHg for placebo) were sustained up to Week 76.

Table 3 Results of a 24 week (LOCF) placebo-controlled study of empagliflozin as add-on to metformin (Full Analysis Set)

Empagliflozin as add-on to metformin therapy	Placebo	Empagliflozin 10 mg	Empagliflozin 25 mg
N	207	217	213
HbA1c (%)			
Baseline (mean)	7.90	7.94	7.86
Change from baseline ¹	-0.13	-0.70	-0.77
Difference from placebo ¹ (97.5% CI)		-0.57* (-0.72, -0.42)	-0.64* (-0.79, -0.48)
N	184	199	191
Patients (%) achieving HbA1c <7% with baseline HbA1c ≥7%²	12.5	37.7	38.7
N	207	216	213
FPG (mmol/L)²			
Baseline (mean)	8.66	8.58	8.29
Change from baseline ¹	0.36	-1.11	-1.24
Difference from placebo ¹ (95% CI)		-1.47* (-1.74, -1.20)	-1.59* (-1.86, -1.32)
N	207	217	213
Body weight (kg)			
Baseline (mean)	79.73	81.59	82.21
Change from baseline ¹	-0.45	-2.08	-2.46
Difference from placebo ¹ (97.5% CI)		-1.63* (-2.17, -1.08)	-2.01* (-2.56, -1.46)
N	207	217	213
Patients (%) achieving weight loss of >5%²	4.8	21.2	23.0
N	207	217	213
SBP (mmHg)²			
Baseline (mean)	128.6	129.6	130.0
Change from baseline ¹	-0.4	-4.5	-5.2
Difference from placebo ¹ (95% CI)		-4.1* (-6.2, -2.1)	-4.8* (-6.9, -2.7)

¹ mean adjusted for baseline value and stratification

² not evaluated for statistical significance ; not part of sequential testing procedure for secondary endpoints

³ last observation (prior to glycemic rescue) carried forward (LOCF)

*p-value <0.0001

FPG - fasting plasma glucose; SBP – systolic blood pressure

Empagliflozin and metformin combination therapy in drug-naïve patients

A factorial design study of 24 weeks duration was conducted to evaluate the efficacy and safety of empagliflozin in drug-naïve patients. The majority of patients had been diagnosed with diabetes for up to a year (55.8%) or for between one and five years (28.6%). Their mean age was 52.6 years and mean BMI was 30.37 kg/m². Treatment with empagliflozin in combination with metformin (5 mg and 500 mg; 5 mg and 1000 mg; 12.5 mg and 500 mg, and 12.5 mg and 1000 mg given twice daily) provided statistically significant improvements in HbA1c and led to significantly greater reductions in FPG and body weight compared to the individual components. A greater proportion of patients with a baseline HbA1c ≥7.0% and treated with empagliflozin in combination with metformin achieved a target HbA1c <7% compared to the individual components (Tables 4 and 5).

Table 4 Results of a 24 weeks (OC)² study comparing empagliflozin 10 mg in combination with metformin to the individual components

	Empagliflozin + metformin		Empagliflozin	Metformin	
	10 mg + 1000 mg ^a	10 mg + 2000 mg ^a	10 mg (qd)	1000 mg ^a	2000 mg ^a
N	161	167	169	167	162
HbA1c (%)					
Baseline (mean)	8.7	8.7	8.6	8.7	8.6
Change from baseline ¹	-2.0	-2.1	-1.4	-1.2	-1.8
Comparison vs. empagliflozin (95% CI) ¹	-0.6*	-0.7*			
Comparison vs. metformin (95% CI) ¹	(-0.9, -0.4) ^b	(-1.0, -0.5) ^b			
	-0.8*	-0.3*			
	(-1.0, -0.6) ^b	(-0.6, -0.1) ^b			
N	153	161	159	166	159
Patients (%) achieving HbA1c <7% with baseline HbA1c ≥7%					
	96 (63%)	112 (70%)	69 (43%)	63 (38%)	92 (58%)
N	161	166	168	165	164
FPG (mmol/L)					
Baseline (mean)	9.2	9.1	9.4	9.6	9.4
Change from baseline ¹	-2.5	-2.7	-1.8	-1.0	-1.8
Comparison vs. empagliflozin (95% CI) ¹	-0.7**	-0.8**			
Comparison vs. metformin (95% CI) ¹	(-1.1, -0.3) ^b	(-1.2, -0.5) ^b			
	-1.6**	-0.9**			
	(-1.9, -1.2) ^b	(-1.2, -0.5) ^b			
N	161	165	168	166	162
Body Weight (kg)					
Baseline (mean)	82.3	83.0	83.9	82.9	83.8
% Change from baseline ¹	-3.1	-4.1	-2.7	-0.4	-1.2
Comparison vs. metformin (95% CI) ¹	-2.7**	-2.8**			
	(-3.6, -1.8) ^b	(-3.8, -1.9) ^b			

^a Given in two equally divided doses per day (5 mg empagliflozin + 500 mg metformin bid or 5 mg empagliflozin + 1000 mg metformin bid, respectively).

^b Full analysis population (observed case) using MMRM. MMRM model included treatment, renal function, region, visit, visit by treatment interaction, and baseline HbA1c; FPG included baseline FPG in addition; weight included baseline weight in addition.

¹ mean adjusted for baseline value

² Analyses were performed on the full analysis set (FAS) using an observed cases (OC) approach

*p≤0.0062 for HbA1c;

**Analysis in an exploratory manner: p≤0.0002 for FPG and p<0.0001 for body weight

FPG - fasting plasma glucose; bid – twice daily; qd – once daily

Table 5 Results of a 24 weeks (OC)² study comparing empagliflozin 25 mg in combination with metformin to the individual monotherapy components

	Empagliflozin + metformin		Empagliflozin	Metformin	
	25 mg + 1000 mg ^a	25 mg + 2000 mg ^a	25 mg qd	1000 mg ^a	2000 mg ^a
N	165	169	163	167	162
HbA1c (%)					
Baseline (mean)	8.8	8.7	8.9	8.7	8.6
Change from baseline ¹	-1.9	-2.1	-1.4	-1.2	-1.8
Comparison vs. empagliflozin (95% CI) ¹	-0.6*	-0.7*			
Comparison vs. metformin (95% CI) ¹	(-0.8, -0.3) ^b	(-1.0, -0.5) ^b			
	-0.8*	-0.3*			
	(-1.0, -0.5) ^b	(-0.6, -0.1) ^b			
N	159	163	158	166	159
Patients (%) achieving HbA1c <7% with baseline HbA1c ≥7%					
	91 (57%)	111 (68%)	51 (32%)	63 (38%)	92 (58%)

	Empagliflozin + metformin		Empagliflozin	Metformin	
	25 mg + 1000 mg ^a	25 mg + 2000 mg ^a	25 mg qd	1000 mg ^a	2000 mg ^a
N	163	167	163	165	164
FPG (mmol/L)					
Baseline (mean)	9.5	9.3	9.8	9.6	9.4
Change from baseline ¹	-2.4	-2.8	-1.6	-1.0	-1.8
Comparison vs. empagliflozin (95% CI) ¹	(-1.3, -0.5) ^b		(-1.6, -0.9) ^b		
Comparison vs. metformin (95% CI) ¹	(-1.9, -1.1) ^b		(-1.4, -0.7) ^b		
N	165	167	162	166	162
Body Weight (kg)					
Baseline (mean)	82.9	83.7	83.4	82.9	83.8
% Change from baseline ¹	-3.6	-4.3	-2.8	-0.4	-1.2
Comparison vs. metformin (95% CI) ¹	(-4.1, -2.2) ^b		(-4.1, -2.2) ^b		

^a Given in two equally divided doses per day (12.5 mg empagliflozin + 500 mg metformin bid or 12.5 mg empagliflozin + 1000 mg metformin bid, respectively).

^b Full analysis population (observed case) using MMRM. MMRM model included treatment, renal function, region, visit, visit by treatment interaction, and baseline HbA1c; FPG included baseline FPG in addition; weight included baseline weight in addition.

¹ mean adjusted for baseline value

² Analyses were performed on the full analysis set (FAS) using an observed cases (OC) approach

*p<0.0056 for HbA1c

** Analysis in an exploratory manner: p<0.0001 for FPG and p<0.0001 for body weight

FPG - fasting plasma glucose; bid – twice daily; qd – once daily

Empagliflozin as add on to a combination of metformin and sulfonylurea therapy

A double-blind, placebo-controlled study of 24 weeks duration was conducted to evaluate the efficacy and safety of empagliflozin in patients not sufficiently treated with a combination of metformin and a sulfonylurea. Treatment with empagliflozin resulted in statistically significant improvements in HbA1c and body weight and clinically meaningful reductions in FPG and BP compared to placebo (Table 6).

In the double-blind placebo-controlled extension of this study, reductions of HbA1c (change from baseline of -0.74% for empagliflozin 10 mg, -0.72% for empagliflozin 25 mg and -0.03% for placebo), body weight (change from baseline of -2.44 kg for empagliflozin 10 mg, -2.28 kg for empagliflozin 25 mg and -0.63 kg for placebo) and BP (systolic BP: change from baseline of -3.8 mmHg for empagliflozin 10 mg, -3.7 mmHg for empagliflozin 25 mg and -1.6 mmHg for placebo, diastolic BP: change from baseline of -2.6 mmHg for empagliflozin 10 mg, -2.3 mmHg for empagliflozin 25 mg and -1.4 mmHg for placebo) were sustained up to Week 76.

Table 6 Results of a 24 week (LOCF) placebo-controlled study of empagliflozin as add-on to metformin and a sulfonylurea (Full Analysis Set)

Empagliflozin as add-on to metformin and a sulfonylurea therapy	Placebo	Empagliflozin 10 mg	Empagliflozin 25 mg
N	225	225	216
HbA1c (%)			
Baseline (mean)	8.15	8.07	8.10
Change from baseline ¹	-0.17	-0.82	-0.77
Difference from placebo ¹ (97.5% CI)		-0.64* (-0.79, -0.49)	-0.59* (-0.74, -0.44)
N	216	209	202
Patients (%) achieving HbA1c <7% with baseline HbA1c ≥7%²	9.3	26.3	32.2

Empagliflozin as add-on to metformin and a sulfonylurea therapy	Placebo	Empagliflozin 10 mg	Empagliflozin 25 mg
N	224	225	215
FPG (mmol/L)²			
Baseline (mean)	8.42	8.38	8.68
Change from baseline ¹	0.31	-1.29	-1.29
Difference from placebo ¹ (95% CI)		-1.60* (-1.90, -1.30)	-1.60* (-1.90, -1.29)
N	225	225	216
Body weight (kg)			
Baseline (mean)	76.23	77.08	77.50
Change from baseline ¹	-0.39	-2.16	-2.39
Difference from placebo ¹ (97.5% CI)		-1.76* (-2.25, -1.28)	-1.99* (-2.48, -1.50)
N	225	225	216
Patients (%) achieving weight loss of >5%²	5.8	27.6	23.6
N	225	225	216
SBP (mmHg)²			
Baseline (mean)	128.8	128.7	129.3
Change from baseline ¹	-1.4	-4.1	-3.5
Difference from placebo ¹ (95% CI)		-2.7 (-4.6, -0.8)	-2.1 (-4.0, -0.2)

¹ mean adjusted for baseline value and stratification

² not evaluated for statistical significance; not part of sequential testing procedure for the secondary endpoints

³ last observation (prior to glycemic rescue) carried forward (LOCF)

*p-value <0.0001

FPG – fasting plasma glucose; SBP – systolic blood pressure

2 hour post-prandial glucose

Treatment with empagliflozin as add-on to metformin or metformin plus sulfonylurea resulted in clinically meaningful improvement of 2-hour post-prandial glucose (meal tolerance test) at 24 weeks (add-on to metformin: -2.55 mmol/L for empagliflozin 10 mg (n=52), -2.48 mmol/L for empagliflozin 25 mg (n=58), 0.33 mmol/L for placebo (n=57); add-on to metformin plus sulfonylurea: -1.98 mmol/L for empagliflozin 10 mg (n=44), -2.03 mmol/L for empagliflozin 25 mg (n=46), -0.13 mmol/L for placebo (n=35)).

Empagliflozin as add on to a combination of pioglitazone therapy (+/- metformin)

The efficacy and safety of empagliflozin in combination with pioglitazone, with or without metformin (75.5% of all patients were on metformin background) was evaluated in a double-blind, placebo-controlled study of 24 weeks duration. Empagliflozin in combination with pioglitazone (mean dose ≥30 mg) with or without metformin resulted in statistically significant reductions in HbA1c, fasting plasma glucose, and body weight and clinically meaningful reductions in BP compared to placebo (Table 7).

In the double-blind placebo-controlled extension of this study, reductions of HbA1c (change from baseline of -0.61% for empagliflozin 10 mg, -0.70% for empagliflozin 25 mg and -0.01% for placebo), body weight (change from baseline of -1.47 kg for empagliflozin 10 mg, -1.21 kg for empagliflozin 25 mg and +0.50 kg for placebo) and BP (systolic BP: change from baseline of -1.7 mmHg for empagliflozin 10 mg, -3.4 mmHg for empagliflozin 25 mg and +0.3 mmHg for placebo, diastolic BP: change from baseline of -1.43 mmHg for empagliflozin 10 mg, -2.0 mmHg for empagliflozin 25 mg and +0.2 mmHg for placebo) were sustained up to Week 76.

Table 7 Results of a 24 week (LOCF) placebo-controlled study of empagliflozin as add-on to pioglitazone with or without metformin (Full Analysis Set)

Empagliflozin as add-on to pioglitazone +/- metformin therapy	Placebo	Empagliflozin 10 mg	Empagliflozin 25 mg
N	165	165	168
HbA1c (%)			
Baseline (mean)	8.16	8.07	8.06
Change from baseline ¹	-0.11	-0.59	-0.72
Difference from placebo ¹ (97.5% CI)		-0.48* (-0.69, -0.27)	-0.61* (-0.82, -0.40)
N	155	151	160
Patients (%) achieving HbA1c <7% with baseline HbA1c ≥7%³	7.7	24	38
N	165	163	168
FPG (mmol/L)			
Baseline (mean)	8.43	8.44	8.43
Change from baseline ¹	0.37	-0.94	-1.23
Difference from placebo ¹ (97.5% CI)		-1.30* (-1.72, -0.91)	-1.58* (-2.04, -1.12)
N	165	165	168
Body weight (kg)			
Baseline (mean)	78.1	77.97	78.93
Change from baseline ¹	0.34	-1.62	-1.47
Difference from placebo ¹ (97.5% CI)		-1.95* (-2.64, -1.27)	-1.81* (-2.49, -1.13)
N	165	165	168
Patients(%) achieving weight loss of >5%³	5.5	18.8	13.7
N	165	165	168
SBP (mmHg)^{2, 3}			
Baseline (mean)	125.7	126.5	126
Change from baseline ¹	0.7	-3.1	-4.0
Difference from placebo ¹ (95% CI)		-3.9 (-6.23, -1.50)	-4.7 (-7.08, -2.37)

¹ mean adjusted for baseline value and stratification

² not evaluated for statistical significance; not part of sequential testing procedure for the secondary endpoints

³ last observation (prior to glycaemic rescue) carried forward (LOCF)

*p-value <0.0001

FPG - fasting plasma glucose, SBP – systolic blood pressure

Empagliflozin and linagliptin as add on therapy to metformin

In a factorial design study, patients inadequately controlled on metformin, 24-weeks treatment with both doses of empagliflozin 10 mg and 25 mg administered together with linagliptin 5 mg provided statistically significant improvements in HbA1c and FPG compared to linagliptin 5 mg and also compared to empagliflozin 10 or 25 mg. Compared to linagliptin 5mg, both doses of empagliflozin plus linagliptin 5 mg provided statistically significant reductions in body weight and blood pressure. A greater proportion of patients with a baseline HbA1c ≥7.0% and treated with empagliflozin plus linagliptin achieved a target HbA1c of <7% compared to linagliptin 5 mg (Table 8).

After 24 weeks' treatment with empagliflozin+linagliptin, both systolic and diastolic blood pressures were reduced, -5.6/-3.6 mmHg (p<0.001 versus linagliptin 5 mg for SBP and DBP) for empagliflozin 25 mg+linagliptin 5 mg and -4.1/-2.6 mmHg (p<0.05 versus linagliptin 5 mg for SBP, n.s. for DBP) for empagliflozin 10 mg+linagliptin 5 mg. Clinically meaningful reductions in blood pressure were maintained for 52 weeks, -3.8/-1.6 mmHg (p<0.05 versus linagliptin 5 mg for SBP and DBP) for empagliflozin 25 mg/linagliptin 5 mg and -3.1/-1.6 mmHg (p<0.05 versus linagliptin 5 mg for SBP, n.s. for DBP) for empagliflozin 10 mg/linagliptin 5 mg.

After 24 weeks, rescue therapy was used in 1 (0.7%) patient treated with empagliflozin 25 mg/linagliptin 5 mg and in 3 (2.2%) patients treated with empagliflozin 10 mg/linagliptin 5 mg, compared to 4 (3.1%) patients treated with linagliptin 5 mg and 6 (4.3%) patients treated with empagliflozin 25 mg and 1 (0.7%) patient treated with empagliflozin 10 mg.

Table 8 Results of a 24 week (OC) placebo-controlled study of empagliflozin and linagliptin as fixed dose combination as add-on therapy to metformin (Full Analysis Set)

	Empagliflozin/linagliptin		Empagliflozin	Linagliptin	
	25 mg/5 mg	10 mg/5 mg	25 mg	10 mg	5 mg
N	134	135	140	137	128
HbA1c (%) – 24 weeks					
Baseline (mean)	7.9	8.0	8.0	8.0	8.0
Change from baseline (adjusted mean)	-1.2	-1.1	-0.6	-0.7	-0.7
Comparison vs. linagliptin 5 mg (adjusted mean) (95% CI) ²	-0.5 (-0.7, -0.3)*	-0.4 (-0.6, -0.2)*			
N	134	135	140	137	128
HbA1c (%) – 52 weeks¹					
Baseline (mean)	7.9	8.0	8.0	8.0	8.0
Change from baseline (adjusted mean)	-1.2	-1.0	-0.7	-0.7	-0.5
Comparison vs. linagliptin 5 mg (adjusted mean) (95% CI) ²	-0.8 (-1.0, -0.6)*	-0.60 (-0.8, -0.4)*			
N	134	135	140	137	128
Body Weight - 24 weeks					
Baseline (mean) in kg	85	87	88	86	85
Change from baseline (adjusted mean)	-3.0	-2.6	-3.2	-2.5	-0.7
Comparison vs. linagliptin 5 mg (adjusted mean) (95% CI) ⁴	-2.3 (-3.2, -1.4)*	-1.9 (-2.8, -1.1)*			
N	123	128	132	125	119
Patients (%) achieving HbA1c <7% with baseline HbA1c ≥7% - 24 weeks					
Comparison vs. linagliptin 5 mg (odds ratio) (95% CI) ³	3.5 (1.9, 6.4)*	2.8 (1.6, 5.0)**			

¹ not evaluated for statistical significance as a result of the sequential confirmatory testing procedure

² Full analysis population (observed case) using MMRM. MMRM model included treatment, renal function, region, visit, visit by treatment interaction, and baseline HbA1c.

³ Full analysis population with non-completers considered failure. Logistic regression included treatment, baseline renal function, geographical region and baseline HbA1c.

⁴ Full analysis population using last observation carried forward. ANCOVA model included treatment, renal function, region, baseline weight, and baseline HbA1c.

*p<0.0001; **p<0.001

Empagliflozin in patients inadequately controlled on metformin and linagliptin

In patients inadequately controlled on metformin and linagliptin 5 mg, 24-weeks treatment with both empagliflozin/linagliptin 10 mg/5 mg and empagliflozin/linagliptin 25 mg/5 mg provided statistically significant improvements in HbA1c, FPG and body weight compared to placebo+linagliptin 5 mg. A statistically significantly greater number of patients with a baseline HbA1c ≥7.0% and treated with both doses of empagliflozin achieved a target HbA1c of <7% compared to placebo+linagliptin 5 mg (Table 9). After 24 weeks' treatment with empagliflozin, both systolic and diastolic blood pressures were reduced, -2.6/-1.1 mmHg (n.s. versus placebo for SBP and DBP) for empagliflozin 25 mg+linagliptin 5 mg and -1.3/-0.1 mmHg (n.s. versus placebo for SBP and DBP) for empagliflozin 10 mg+linagliptin 5 mg.

After 24 weeks, rescue therapy was used in 4 (3.6%) patients treated with empagliflozin 25 mg+linagliptin 5 mg and in 2 (1.8%) patients treated with empagliflozin 10 mg+linagliptin 5 mg, compared to 13 (12.0%) patients treated with placebo+linagliptin 5 mg.

Table 9 Efficacy Parameters Comparing Empagliflozin to Placebo as Add-on Therapy in Patients Inadequately Controlled on Metformin and Linagliptin 5 mg

	Metformin + Linagliptin 5 mg		
	Empagliflozin 10 mg ¹	Empagliflozin 25 mg ¹	Placebo ²
HbA1c (%) - 24 weeks³			
N	109	110	106
Baseline (mean)	7.97	7.97	7.96
Change from baseline (adjusted mean)	-0.65	-0.56	0.14
Comparison vs. placebo (adjusted mean) (95% CI) ²	-0.79 (-1.02, -0.55) p<0.0001	-0.70 (-0.93, -0.46) p<0.0001	
FPG (mmol/L) – 24 weeks³			
N	109	109	106
Baseline (mean)	9.3	9.5	9.1
Change from baseline (adjusted mean)	-1.5	-1.8	0.3
Comparison vs. placebo (adjusted mean) (95% CI)	-1.8 (-2.3, -1.3) p<0.0001	-2.1 (-2.6, -1.6) p<0.0001	
Body Weight-24 weeks³			
N	109	110	106
Baseline (mean) in kg	88.4	84.4	82.3
Change from baseline (adjusted mean)	-3.1	-2.5	-0.3
Comparison vs. placebo (adjusted mean) (95% CI) ¹	-2.8 (-3.5, -2.1) p<0.0001	-2.2 (-2.9, -1.5) p<0.0001	
Patients (%) achieving HbA1c <7% with baseline HbA1c ≥7% - 24 weeks⁴			
N	100	107	100
Patients (%) achieving A1C <7%	37.0	32.7	17.0
Comparison vs. placebo (odds ratio) (95% CI) ⁵	4.0 (1.9, 8.7) p=0.0004	2.9 (1.4, 6.1) p=0.0061	

¹ Patients randomised to the empagliflozin 10 mg or 25 mg groups were receiving empagliflozin/linagliptin 10 mg/5 mg or 25 mg/5 mg with background metformin

² Patients randomised to the placebo group were receiving the placebo plus linagliptin 5 mg with background metformin

³ MMRM model on FAS (OC) includes baseline HbA1c, baseline eGFR (MDRD), geographical region, visit treatment, and treatment by visit interaction. For FPG, baseline FPG is also included. For weight, baseline weight is also included.

⁴ not evaluated for statistical significance; not part of sequential testing procedure for the secondary endpoints

⁵ Logistic regression on FAS (NCF) includes baseline HbA1c, baseline eGFR (MDRD), geographical region, and treatment; based on patients with HbA1c of 7% and above at baseline

In a prespecified subgroup of patients with baseline HbA1c greater or equal than 8.5% the reduction from baseline in HbA1c with empagliflozin 25 mg+linagliptin 5 mg was -1.3% at 24 weeks (p<0.0001 versus placebo+linagliptin 5 mg) and with empagliflozin 10 mg+linagliptin 5 mg -1.3% at 24 weeks (p<0.0001 versus placebo+linagliptin 5 mg).

Empagliflozin 2-year data, as add on to metformin in comparison to glimepiride

In a study comparing the efficacy and safety of empagliflozin 25 mg versus glimepiride (1-4 mg) in patients with inadequate glycaemic control on metformin alone, treatment with empagliflozin daily resulted in superior reduction in HbA1c, and a clinically meaningful reduction in FPG, compared to glimepiride (Table 10). Empagliflozin daily resulted in a statistically significant reduction in body weight, systolic and diastolic BP (change from baseline in diastolic BP of -1.8 mmHg for empagliflozin and +0.9 mmHg for glimepiride, p<0.0001).

Treatment with empagliflozin resulted in statistically significantly lower proportion of patients with hypoglycaemic events compared to glimepiride (2.5% for empagliflozin, 24.2% for glimepiride, p<0.0001).

Table 10 Results at 104 week (LOCF) ⁴ in an active controlled study comparing empagliflozin to glimepiride as add on to metformin (Full Analysis Set)

Empagliflozin as add-on to metformin therapy in comparison to glimepiride	Empagliflozin 25 mg	Glimepiride (up to 4 mg)
N	765	780
HbA1c (%)		
Baseline (mean)	7.92	7.92
Change from baseline ¹	-0.66	-0.55
Difference from glimepiride ¹ (97.5% CI)	-0.11* (-0.20, -0.01)	
N	690	715
Patients (%) achieving HbA1c <7% with baseline HbA1c ≥7%²	33.6	30.9
N		
FPG (mmol/L)		
Baseline (mean)	8.32	8.31
Change from baseline ¹	-0.85	-0.17
Difference from glimepiride ¹ (95% CI)	-0.69** (-0.86, -0.51)	
N	765	780
Body weight (kg)		
Baseline (mean)	82.52	83.03
Change from baseline ¹	-3.12	1.34
Difference from glimepiride ¹ (97.5% CI)	-4.46** (-4.87, -4.05)	
N	765	780
Patients(%) achieving weight loss of >5%²	27.5	3.8
N	765	780
SBP (mmHg)³		
Baseline (mean)	133.4	133.5
Change from baseline ¹	-3.1	2.5
Difference from glimepiride ¹ (97.5% CI)	-5.6** (-7.0,-4.2)	

¹ mean adjusted for baseline value and stratification

² not evaluated for statistical significance ; not part of sequential testing procedure for the secondary endpoints

³ LOCF, values after antihypertensive rescue censored

⁴ last observation (prior to glycemic rescue) carried forward (LOCF)

* p-value <0.0001 for non-inferiority, and p-value = 0.0153 for superiority

** p-value <0.0001

FPG - fasting plasma glucose, SBP – systolic blood pressure

Empagliflozin as add on to basal insulin therapy

The efficacy and safety of empagliflozin as add on to basal insulin with or without concomitant metformin and/or sulfonylurea therapy (79.8% of all patients were on metformin background) was evaluated in a double-blind, placebo-controlled trial of 78 weeks duration. During the initial 18 weeks the insulin dose was to be kept stable, but was adjusted to achieve a FPG <6.10 mmol/L in the following 60 weeks.

At week 18, empagliflozin provided statistically significant improvement in HbA1c compared to placebo. A greater proportion of patients with a baseline HbA1c ≥7.0% achieved a target HbA1c of <7% compared to placebo. At 78 weeks, empagliflozin resulted in a statistically significant decrease in HbA1c and insulin sparing compared to placebo (Table 11).

At week 78, empagliflozin resulted in a reduction in FPG (-0.58 mmol/L for empagliflozin 10 mg, -0.97 mmol/L for empagliflozin 25 mg and -0.30 mmol/L for placebo), body weight (-2.47 kg for empagliflozin 10 mg, -1.96 kg for empagliflozin 25 mg and +1.16 kg for placebo, p<0.0001), BP (systolic BP: -4.1 mmHg for empagliflozin 10 mg, -2.4 mmHg for empagliflozin 25 mg and 0.1 mmHg for placebo, diastolic BP: -2.9 mmHg for empagliflozin 10 mg, -1.5 mmHg for empagliflozin 25 mg and -0.3 mmHg for placebo).

Table 11 Results at 18 and 78 weeks (LOCF)² in a placebo-controlled study of empagliflozin as add on to basal insulin with or without metformin and/or sulfonylurea (Full Analysis Set - Completers)

Empagliflozin add-on to basal insulin +/- metformin or sulfonylurea therapy	Placebo	Empagliflozin 10 mg	Empagliflozin 25 mg
N	125	132	117
HbA1c (%) at week 18			
Baseline (mean)	8.10	8.26	8.34
Change from baseline ¹	-0.01	-0.57	-0.71
Difference from placebo ¹ (97.5% CI)		-0.56* (-0.78, -0.33)	-0.70* (-0.93, -0.47)
N	112	127	110
HbA1c (%) at week 78			
Baseline (mean)	8.09	8.27	8.29
Change from baseline ¹	-0.02	-0.48	-0.64
Difference from placebo ¹ (97.5% CI)		-0.46* (-0.73, -0.19)	-0.62* (-0.90, -0.34)
N	112	127	110
Basal insulin dose (IU/day) at week 78			
Baseline (mean)	47.84	45.13	48.43
Change from baseline ¹	5.45	-1.21	-0.47
Difference from placebo ¹ (97.5% CI)		-6.66*** (-11.56, -1.77)	-5.92*** (-11.00, -0.85)

¹ mean adjusted for baseline value and stratification

² last observation (prior to glycemic rescue) carried forward (LOCF)

*p-value <0.0001; ***p-value <0.01

Empagliflozin as add on to MDI insulin therapy and metformin

The efficacy and safety of empagliflozin as add-on to multiple daily insulin with or without concomitant metformin therapy (71.0% of all patients were on metformin background) was evaluated in a double-blind, placebo-controlled trial of 52 weeks duration. During the initial 18 weeks and the last 12 weeks, the insulin dose was kept stable, but was adjusted to achieve pre-prandial glucose levels <5.5 mmol/L, and post-prandial glucose levels <7.8 mmol/L between Weeks 19 and 40.

At Week 18, empagliflozin provided statistically significant improvement in HbA1c compared with placebo (Table 12). A greater proportion of patients with a baseline HbA1c ≥7.0% (19.5% empagliflozin 10 mg, 31.0% empagliflozin 25 mg) achieved a target HbA1c of <7% compared with placebo (15.1%).

At Week 52, treatment with empagliflozin resulted in a statistically significant decrease in HbA1c and insulin sparing compared with placebo and a reduction in FPG (change from baseline of -0.02 mmol/L for placebo, -1.09 mmol/L for empagliflozin 10 mg, and -1.31 mmol/L for empagliflozin 25 mg), body weight, and BP (systolic BP: change from baseline of -2.6 mmHg for placebo, -3.9 mmHg for empagliflozin 10 mg and -4.0 mmHg for empagliflozin 25 mg, diastolic BP: change from baseline of -1.0 mmHg for placebo, -1.4 mmHg for empagliflozin 10 mg and -2.6 mmHg for empagliflozin 25 mg).

Table 12 Results at 18 and 52 (LOCF)⁵ weeks in a placebo-controlled study of empagliflozin as add on to multiple daily doses of insulin with metformin²

Empagliflozin as add-on to insulin + metformin therapy	Placebo	Empagliflozin 10 mg	Empagliflozin 25 mg
N	188	186	189
HbA1c (%) at week 18			
Baseline (mean)	8.33	8.39	8.29
Change from baseline ¹	-0.50	-0.94	-1.02
Difference from placebo ¹ (97.5% CI)		-0.44* (-0.61, -0.27)	-0.52* (-0.69, -0.35)

Empagliflozin as add-on to insulin + metformin therapy	Placebo	Empagliflozin 10 mg	Empagliflozin 25 mg
HbA1c (%) at week 52³			
N	115	119	118
Baseline (mean)	8.25	8.40	8.37
Change from baseline ¹	-0.81	-1.18	-1.27
Difference from placebo ¹ (97.5% CI)		-0.38** (-0.62, -0.13)	-0.46* (-0.70, -0.22)
Patients (%) achieving HbA1c <7% with baseline HbA1c ≥7% at week 52⁴			
N	113	118	118
26.5		39.8	45.8
FPG (mmol/L) at week 52⁵			
N	188	186	189
Baseline (mean)	8.41	8.83	8.34
Change from baseline ¹	-0.02	-1.09	-1.31
Difference from placebo ¹		-1.07 (-1.55, -0.6)	-1.30 (-1.77, -0.83)
Insulin dose (IU/day) at week 52³			
N	115	118	117
Baseline (mean)	89.94	88.57	90.38
Change from baseline ¹	10.16	1.33	-1.06
Difference from placebo ¹ (97.5% CI)		-8.83** (-15.69, -1.97)	-11.22** (-18.09, -4.36)
Body weight (kg) at week 52³			
N	115	119	118
Baseline (mean)	96.34	96.47	95.37
Change from baseline ¹	0.44	-1.95	-2.04
Difference from placebo ¹ (97.5% CI)		-2.39* (-3.54, -1.24)	-2.48* (-3.63, -1.33)
SBP (mmHg)⁵			
N	188	186	189
Baseline (mean)	132.6	134.2	132.9
Change from baseline ¹	-2.6	-3.9	-4.0
Difference from placebo ^{1,4} (95% CI)		-1.4 (-3.6, 0.9)	-1.4 (-3.7, 0.8)

¹ mean adjusted for baseline value

² Week 18: FAS; week 52: PPS-Completers-52

³ Week 19-40: treat-to-target regimen for insulin dose adjustment to achieve pre-defined glucose target levels (pre-prandial <5.5 mmol/L, post-prandial <7.8 mmol/L)

⁴ not evaluated for statistical significance as a result of the sequential confirmatory testing procedure

⁵ Last observation (prior to glycaemic rescue) carried forward (LOCF)

⁶ Week 52: FAS

* p-value <0.0001; ** p-value <0.001

Empagliflozin twice daily versus once daily as add on to metformin therapy

The efficacy and safety of empagliflozin twice daily versus once daily (daily dose of 10 mg and 25 mg) as add-on therapy in patients with insufficient glycaemic control on metformin monotherapy was evaluated in a double blind placebo-controlled study of 16 weeks duration. All treatments with empagliflozin resulted in significant reductions in HbA1c from baseline (total mean 7.8%) after 16 weeks of treatment compared with placebo. Empagliflozin twice daily dose regimens led to comparable reductions in HbA1c versus once daily dose regimens with a treatment difference in HbA1c reductions from baseline to week 16 of -0.02% (95% CI -0.16, 0.13) for empagliflozin 5 mg twice daily vs. 10 mg once daily, and -0.11% (95% CI -0.26, 0.03) for empagliflozin 12.5 mg twice daily vs. 25 mg once daily.

Patients with baseline HbA1c ≥9%

In a pre-specified analysis of subjects with baseline HbA1c ≥9.0%, treatment with empagliflozin 10 mg or 25 mg as add-on to metformin resulted in statistically significant reductions in HbA1c at Week 24 (adjusted mean change from baseline of -1.49% for empagliflozin 25 mg, -1.40% for empagliflozin 10 mg, and -0.44% for placebo).

Body weight

In a pre-specified pooled analysis of 4 placebo controlled studies, treatment with empagliflozin (68% of all patients were on metformin background) resulted in body weight reduction compared to placebo at week 24 (-2.04 kg for empagliflozin 10 mg, -2.26 kg for empagliflozin 25 mg and -0.24 kg for placebo) that was maintained up to week 52 (-1.96 kg for empagliflozin 10 mg, -2.25 kg for empagliflozin 25 mg and -0.16 kg for placebo).

Blood pressure

The efficacy and safety of empagliflozin was evaluated in a double-blind, placebo controlled study of 12 weeks duration in patients with type 2 diabetes and high blood pressure on different antidiabetic (67.8% treated with metformin with or without other antidiabetic drugs including insulin) and up to 2 antihypertensive therapies (Table 13). Treatment with empagliflozin once daily resulted in statistically significant improvement in HbA1c, 24 hour mean systolic and diastolic blood pressure as determined by ambulatory BP monitoring. Treatment with empagliflozin provided reductions in seated systolic BP (change from baseline of -0.67 mmHg for placebo, -4.60 mmHg for empagliflozin 10 mg and -5.47 mmHg for empagliflozin 25 mg) and seated diastolic BP (change from baseline of -1.13 mmHg for placebo, -3.06 mmHg for empagliflozin 10 mg and -3.02 mmHg for empagliflozin 25 mg).

Table 13 Results at 12 week (LOCF) in a placebo-controlled study of empagliflozin in patients with type 2 diabetes and uncontrolled blood pressure (Full Analysis Set)

	Placebo	Empagliflozin 10 mg	Empagliflozin 25 mg
N	271	276	276
HbA1c (%) at week 12			
Baseline (mean)	7.90	7.87	7.92
Change from baseline ¹	0.03	-0.59	-0.62
Difference from placebo ¹ (95% CI)		-0.62* (-0.72, -0.52)	-0.65* (-0.75, -0.55)
24 hour SBP at week 12²			
Baseline (mean)	131.72	131.34	131.18
Change from baseline ¹	0.48	-2.95	-3.68
Difference from placebo ¹ (95% CI)		-3.44* (-4.78, -2.09)	-4.16* (-5.50, -2.83)
24 hour DBP at week 12²			
Baseline (mean)	75.16	75.13	74.64
Change from baseline ¹	0.32	-1.04	-1.40
Difference from placebo ¹ (95% CI)		-1.36** (-2.15, -0.56)	-1.72* (-2.51, -0.93)

¹ Mean adjusted for baseline value and stratification

² Last observation (prior to antihypertensive rescue) carried forward (LOCF)

³ Last observation (prior to glycemic rescue) carried forward (LOCF)

* p-value <0.0001; ** p-value =0.0008

SBP – systolic blood pressure, DBP – diastolic blood pressure

In a pre-specified pooled analysis of 4 placebo-controlled studies, treatment with empagliflozin (68% of all patients were on metformin background) resulted in a reduction in systolic blood pressure (empagliflozin 10 mg -3.9 mmHg, empagliflozin 25 mg -4.3 mmHg) compared with placebo (-0.5 mmHg), and in diastolic blood pressure (empagliflozin 10 mg -1.8 mmHg, empagliflozin 25 mg -2.0 mmHg) compared with placebo (-0.5 mmHg), at week 24, that were maintained up to week 52.

Cardiovascular outcome

Empagliflozin is indicated in patients with type 2 diabetes mellitus and established cardiovascular disease to reduce the risk of cardiovascular death. However, the effectiveness of JARDIEMET on reducing the risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease has not been established. The effect of empagliflozin on cardiovascular risk in adult patients with type 2 diabetes and established cardiovascular disease is presented below.

The EMPA-REG OUTCOME study is a multi-centre, multi-national, randomised, double-blind, placebo-controlled trial investigating the effect of empagliflozin as adjunct to standard care therapy in reducing cardiovascular events in patients with type 2 diabetes and one or more cardiovascular risk factors, including coronary artery disease, peripheral artery disease, history of myocardial infarction (MI), or history of stroke. The primary endpoint was the time to first event in the composite of CV death, nonfatal MI, or non-fatal stroke (Major Adverse Cardiovascular Events (MACE-3)). Additional pre-specified endpoints addressing clinically relevant outcomes tested in an exploratory manner included CV death, the composite of heart failure requiring hospitalisation or CV death, all-cause mortality and the composite of new or worsening nephropathy.

A total of 7020 patients were treated with empagliflozin (empagliflozin 10 mg: 2345, empagliflozin 25 mg: 2342, placebo: 2333) and followed for a median of 3.1 years. Approximately 74% of patients were being treated with metformin at baseline, 48% with insulin and 43% with sulfonylurea.

The population was 72.4% Caucasian, 21.6% Asian, and 5.1% Black. The mean age was 63 years and 71.5% were male. At baseline, approximately 81% of patients were being treated with renin angiotensin system inhibitors, 65% with beta-blockers, 43% with diuretics, 89% with anticoagulants, and 81% with lipid lowering medication.

About half of the patients (52.2%) had an eGFR of 60-90 mL/min/1.73 m², 17.8% of 45-60 mL/min/1.73 m² and 7.7% of 30-45 mL/min/1.73 m². Mean systolic BP was 136 mmHg, diastolic BP 76 mmHg, low density lipoprotein (LDL) 2.2 mmol/L, high density lipoprotein (HDL) 1.1 mmol/L, and urinary albumin to creatinine ratio (UACR) 19.8 mg/mmol at baseline.

Reductions in risk of CV death and overall mortality

Empagliflozin is superior in reducing the primary composite endpoint of cardiovascular death, non-fatal MI, or non-fatal stroke compared to placebo. The treatment effect reflected a reduction in cardiovascular death with no significant change in non-fatal MI, or non-fatal stroke (Table 14 and Figure 1).

Empagliflozin also improved overall survival (Table 12), which was driven by a reduction in cardiovascular death with empagliflozin. There was no statistically significant difference between empagliflozin and placebo in non-cardiovascular mortality.


Table 14 Treatment effect for the primary composite endpoint, its components and mortality (Treated Set*)

	Placebo	Empagliflozin (10 and 25 mg, pooled)
N	2333	4687
Time to first occurrence of CV death, non-fatal MI, or non-fatal stroke) N (%)	282 (12.1)	490 (10.5)
Hazard ratio vs. placebo (95.02% CI)**		0.86 (0.74, 0.99)
p-value for superiority		0.0382
CV Death N (%)	137 (5.9)	172 (3.7)
Hazard ratio vs. placebo (95% CI)		0.62 (0.49, 0.77)
p-value		<0.0001
Non-fatal MI N (%)	121 (5.2)	213 (4.5)
Hazard ratio vs. placebo (95% CI)		0.87 (0.70, 1.09)
p-value		0.2189
Non-fatal stroke N (%)	60 (2.6)	150 (3.2)
Hazard ratio vs. placebo (95% CI)		1.24 (0.92, 1.67)
p-value		0.1638
All-cause mortality N (%)	194 (8.3)	269 (5.7)
Hazard ratio vs. placebo (95% CI)		0.68 (0.57, 0.82)
p-value		<0.0001
Non-CV mortality N (%)	57 (2.4)	97 (2.1)
Hazard ratio vs. placebo (95% CI)		0.84 (0.60, 1.16)

* i.e. patients who had received at least one dose of study drug

** Since data from the trial were included in an interim analysis, a two-sided 95.02% confidence interval applied which corresponds to a p-value of less than 0.0498 for significance.

Figure 1 Time to occurrence of CV death



Reductions in risk of heart failure requiring hospitalisation or CV death

Empagliflozin is superior in reducing the risk of hospitalisation for heart failure and cardiovascular death or hospitalisation for heart failure compared with placebo (Table 15 and Figure 2).

Table 15 Treatment effect for hospitalisation for heart failure or cardiovascular death (excluding fatal stroke) (Treated Set*)


	Placebo	Empagliflozin** (10 and 25 mg, pooled)
N	2333	4687
Heart failure requiring hospitalisation or CV death (excluding fatal stroke) N (%)***	198 (8.5)	265 (5.7)
HR (95% CI)		0.66 (0.55, 0.79)
p-value		<0.0001
Heart failure requiring hospitalisation N (%)	95 (4.1)	126 (2.7)
HR (95% CI)		0.65 (0.50, 0.85)
p-value		0.0017
CV death (excluding fatal stroke) N (%)	126 (5.4)	156 (3.3)
HR (95% CI)		0.61 (0.48, 0.77)
p-value		<0.0001

*i.e. patients who had received at least one dose of study drug

**empagliflozin 10 mg and 25 mg showed consistent results

*** time to first event

Figure 2 Time to first occurrence of first heart failure hospitalisation or CV death*



*Estimated cumulative incidence function for time to first occurrence of first heart failure hospitalisation or CV death, pooled empagliflozin vs placebo – treated set

The cardiovascular benefits (CV death and hospitalisation for heart failure or CV death) of empagliflozin observed were consistent across the major demographic and disease subgroups.

In the subgroup of patients who were on metformin at baseline, the effects on CV outcomes were consistent with the results observed in the entire study population of EMPA-REG OUTCOME.

Diabetic kidney disease

In the EMPA-REG OUTCOME study population, the risk of new or worsening nephropathy (defined as onset of macroalbuminuria, doubling of serum creatinine, and initiation of renal

replacement therapy (i.e. haemodialysis)) was significantly reduced in empagliflozin group compared to placebo (Table 16 and Figure 3).

Empagliflozin compared with placebo showed a significantly higher occurrence of sustained normo- or microalbuminuria in patients with baseline macroalbuminuria (HR 1.82, 95% CI 1.40, 2.37).

Table 16 Time to first new or worsening of nephropathy (Treated Set*)

	Placebo	Empagliflozin (10 and 25 mg, pooled)
N	2061	4124
New or worsening nephropathy N (%)	388 (18.8)	525 (12.7)
HR (95% CI)		0.61 (0.53, 0.70)
p-value		<0.0001
N	2323	4645
Doubling of serum creatinine level**N (%)	60 (2.6)	70 (1.5)
HR (95% CI)		0.56 (0.39, 0.79)
p-value		0.0009
N	2033	4091
New onset of macroalbuminuria*** N (%)	330 (16.2)	459 (11.2)
HR (95% CI)		0.62 (0.54, 0.72)
p-value		<0.0001
N	2333	4687
Initiation of continuous renal replacement therapy N (%)	14 (0.6)	13 (0.3)
HR (95% CI)		0.45 (0.21, 0.97)
p-value		0.0409
N	2333	4687
Death due to renal disease N (%)****	0	3 (0.1)


* i.e. patients who had received at least one dose of study drug

**Accompanied by an eGFR ≤ 45 mL/min/1.73m²

*** Urine Albumin Creatinine Ratio >33.9 mg/mmol


**** Due to low event rate, HR not calculated

Figure 3 Time to first new or worsening of nephropathy



Treatment with empagliflozin preserved eGFR and eGFR increased during the post treatment 4-week follow up. However, the placebo group showed a gradual decline in GFR during the course of the study with no further change during 4-week follow up (see Figure 4).

Figure 4 eGFR over time*



*eGFR (MDRD) (mL/min/1.73m²) MMRM results over time, unadjusted last value on treatment and follow-up value - treated set – right side based on patients with available last value on treatment (LVOT) and follow-up (FU).

In the subgroup of patients who were on metformin at baseline, the effects on these renal outcomes were consistent with the results observed in the entire study population of EMPA-REG OUTCOME.

Thorough QTc study

In a randomised, placebo-controlled, active-comparator, crossover study of 30 healthy subjects no increase in QTc was observed with either 25 mg or 200 mg empagliflozin.

5.2 PHARMACOKINETIC PROPERTIES

The results of bioequivalence studies in healthy subjects demonstrated that JARDIAMET (empagliflozin/metformin hydrochloride) 5 mg/500 mg, 5 mg/850 mg, 5 mg/1000 mg, 12.5 mg/500 mg, 12.5 mg/850 mg, and 12.5 mg/1000 mg combination tablets are bioequivalent to co-administration of corresponding doses of empagliflozin and metformin as individual tablets.

Administration of 12.5 mg empagliflozin/1000 mg metformin under fed conditions resulted in a 9% decrease in AUC and a 28% decrease in C_{max} for empagliflozin, when compared to fasted conditions. For metformin, AUC decreased by 12% and C_{max} decreased by 26% compared to fasting conditions. The observed effect of food on empagliflozin and metformin is not considered to be clinically relevant. However, as metformin is recommended to be given with meals, JARDIAMET is also proposed to be given with food.

The following statements reflect the pharmacokinetic properties of the individual active substances of JARDIAMET.

Empagliflozin

Absorption

The pharmacokinetics of empagliflozin have been extensively characterised in healthy volunteers and patients with T2DM. After oral administration, empagliflozin was rapidly absorbed with peak plasma concentrations occurring at a median t_{max} 1.5 h post-dose. Thereafter, plasma concentrations declined in a biphasic manner with a rapid distribution phase and a relatively slow terminal phase. The steady state mean plasma AUC and C_{max} were 1870 nmol·h and 259 nmol/L with empagliflozin 10 mg and 4740 nmol·h and 687 nmol/L with empagliflozin 25 mg once daily, respectively. Systemic exposure of empagliflozin increased in a dose-proportional manner. The single-dose and steady-state pharmacokinetics parameters of empagliflozin were similar suggesting linear pharmacokinetics with respect to time. There were no clinically relevant differences in empagliflozin pharmacokinetics between healthy volunteers and patients with T2DM.

The pharmacokinetics of 5 mg empagliflozin twice daily and 10 mg empagliflozin once daily were compared in healthy subjects. Overall exposure (AUC_{ss}) of empagliflozin over a 24-hour period with 5 mg administered twice daily was similar to 10 mg administered once daily. As expected, empagliflozin 5 mg administered twice daily compared with 10 mg empagliflozin once daily resulted in lower C_{max} and higher trough plasma empagliflozin concentrations (C_{min}).

Administration of 25 mg empagliflozin after intake of a high-fat and high calorie meal resulted in slightly lower exposure; AUC decreased by approximately 16% and C_{max} decreased by approximately 37%, compared to fasted condition. The observed effect of food on empagliflozin pharmacokinetics was not considered clinically relevant and empagliflozin may be administered with or without food.

Distribution

The apparent steady-state volume of distribution was estimated to be 73.8 L, based on a population pharmacokinetic analysis. Following administration of an oral [^{14}C]-empagliflozin solution to healthy subjects, the red blood cell partitioning was approximately 36.8% and plasma protein binding was 86.2%.

Metabolism

No major metabolites of empagliflozin were detected in human plasma and the most abundant metabolites were three glucuronide conjugates (2-O-, 3-O-, and 6-O-glucuronide). Systemic exposure of each metabolite was less than 10% of total drug-related material. *In vitro* studies suggested that the primary route of metabolism of empagliflozin in humans is glucuronidation by the uridine 5'-diphospho-glucuronosyltransferases, UGT1A3, UGT1A8, UGT1A9, and UGT2B7.

Excretion

The apparent terminal elimination half-life of empagliflozin was estimated to be 12.4 h and apparent oral clearance was 10.6 L/h based on the population pharmacokinetic analysis. The inter-subject and residual variabilities for empagliflozin oral clearance were 39.1% and 35.8%, respectively. With once-daily dosing, steady-state plasma concentrations of empagliflozin were reached by the fifth dose. Consistent with the half-life, up to 22% accumulation, with respect to plasma AUC, was observed at steady-state. Following administration of an oral [^{14}C]-empagliflozin solution to healthy subjects, approximately 95.6% of the drug related radioactivity was eliminated in faeces (41.2%) or urine (54.4%). The majority of drug related radioactivity recovered in faeces was unchanged parent drug and approximately half of drug related radioactivity excreted in urine was unchanged parent drug.

Metformin hydrochloride

Absorption

After an oral dose of metformin, t_{max} is reached in 2.5 hours. Absolute bioavailability of a 500 mg or 850 mg metformin hydrochloride tablet is approximately 50-60% in healthy subjects. After an oral dose, the non-absorbed fraction recovered in faeces was 20-30%.

After oral administration, metformin hydrochloride absorption is saturable and incomplete. It is assumed that the pharmacokinetics of metformin hydrochloride absorption are non-linear.

At the recommended metformin hydrochloride doses and dosing schedules, steady state plasma concentrations are reached within 24 to 48 hours and are generally less than 1 microgram/mL. In controlled clinical trials, maximum metformin hydrochloride plasma levels (C_{max}) did not exceed 5 microgram/mL, even at maximum doses.

Food decreases the extent and slightly delays the absorption of metformin hydrochloride. Following administration of a dose of 850 mg, a 40% lower plasma peak concentration, a 25% decrease in AUC (area under the curve) and a 35 minute prolongation of the time to peak plasma concentration were observed. The clinical relevance of these decreases is unknown.

Distribution

Plasma protein binding is negligible. Metformin hydrochloride partitions into erythrocytes. The blood peak is lower than the plasma peak and appears at approximately the same time. The red blood cells most likely represent a secondary compartment of distribution. The mean volume of distribution (V_d) ranged between 63-276 L.

Metabolism

Metformin is excreted unchanged in the urine and does not undergo hepatic metabolism.

Excretion

Renal clearance of metformin hydrochloride is >400 mL/min, indicating that metformin hydrochloride is eliminated by glomerular filtration and tubular secretion. Following an oral dose, the apparent terminal elimination half-life is approximately 6.5 hours.

When renal function is impaired, renal clearance is decreased in proportion to that of creatinine and thus the elimination half-life is prolonged, leading to increased levels of metformin hydrochloride in plasma.

Pharmacokinetics in special patient groups

Paediatric

Empagliflozin

Studies characterising the pharmacokinetics of empagliflozin in paediatric patients have not been performed.

Metformin hydrochloride

Single dose study: After single doses of metformin 500 mg, paediatric patients have shown a similar pharmacokinetic profile to that observed in healthy adults.

Multiple dose study: Data are restricted to one study. After repeated doses of 500 mg twice daily for 7 days in paediatric patients the peak plasma concentration (C_{max}) and systemic exposure (AUC_{0-t}) were reduced by approximately 33% and 40%, respectively compared to diabetic adults who received repeated doses of 500 mg twice daily for 14 days. As the dose is individually titrated based on glycaemic control, this is of limited clinical relevance.

Elderly

Empagliflozin

Age did not have a clinically meaningful impact on the pharmacokinetics of empagliflozin based on the population pharmacokinetic analysis.

Metformin hydrochloride

Limited data from controlled pharmacokinetic studies of metformin hydrochloride in healthy elderly subjects suggest that total plasma clearance of metformin hydrochloride is decreased, the half-life is prolonged, and C_{max} is increased, compared to healthy young subjects. From these data, it appears that the change in metformin hydrochloride pharmacokinetics with aging is primarily accounted for by a change in renal function.

JARDIAMET treatment should not be initiated in patients ≥ 80 years of age unless measurement of creatinine clearance demonstrates that renal function is not reduced.

Body Mass Index (BMI)

Empagliflozin

No dosage adjustment is necessary based on BMI. Body mass index had no clinically relevant effect on the pharmacokinetics of empagliflozin based on the population pharmacokinetic analysis.

Gender

Empagliflozin

No dosage adjustment is necessary based on gender. Gender had no clinically relevant effect on the pharmacokinetics of empagliflozin based on the population pharmacokinetic analysis.

Metformin hydrochloride

Metformin hydrochloride pharmacokinetic parameters did not differ significantly between normal subjects and patients with type 2 diabetes when analysed according to gender. Similarly, in controlled clinical studies in patients with type 2 diabetes, the antihyperglycaemic effect of metformin hydrochloride was comparable in males and females.

Race

Empagliflozin

No dosage adjustment is necessary based on race. Based on the population pharmacokinetic analysis, AUC was estimated to be 13.5% higher in Asian patients with a BMI of 25 kg/m² compared to non-Asian patients with a BMI of 25 kg/m².

Metformin hydrochloride

No studies of metformin hydrochloride pharmacokinetic parameters according to race have been performed. In controlled clinical studies of metformin hydrochloride in patients with type 2 diabetes, the antihyperglycaemic effect was comparable in white (n=249), black (n=51) and Hispanic (n=24) patients.

Renal impairment

Empagliflozin

In patients with mild (eGFR: 60 - <90 mL/min/1.73m²), moderate (eGFR: 30 - <60 mL/min/1.73m²), severe (eGFR: <30 mL/min/1.73m²) renal impairment and patients with kidney failure/ESRD patients, AUC of empagliflozin increased by approximately 18%, 20%, 66%, and 48%, respectively, compared to subjects with normal renal function. Peak plasma levels of empagliflozin were similar in subjects with moderate renal impairment and kidney failure/ESRD compared to patients with normal renal function. Peak plasma levels of empagliflozin were roughly 20% higher in subjects with mild and severe renal impairment as

compared to subjects with normal renal function. In line with the Phase I study, the population pharmacokinetic analysis showed that the apparent oral clearance of empagliflozin decreased with a decrease in eGFR leading to an increase in drug exposure. Based on pharmacokinetics, no dosage adjustment is recommended in patients with renal impairment.

Metformin hydrochloride

In patients with decreased renal function (based on measured creatinine clearance), the plasma and blood half-life of metformin hydrochloride is prolonged and the renal clearance is decreased in proportion to the decrease in creatinine clearance.

Hepatic impairment

Empagliflozin

In subjects with mild, moderate, and severe hepatic impairment according to the Child-Pugh classification, AUC of empagliflozin increased approximately by 23%, 47%, and 75% and C_{max} by approximately 4%, 23%, and 48%, respectively, compared to subjects with normal hepatic function. Based on pharmacokinetics, no dosage adjustment is recommended in patients with hepatic impairment.

Metformin hydrochloride

No pharmacokinetic studies of metformin hydrochloride have been conducted in subjects with hepatic impairment.

5.3 PRECLINICAL SAFETY DATA

Genotoxicity

Empagliflozin

Empagliflozin was not mutagenic or clastogenic in a battery of genotoxicity studies, including the Ames bacterial mutagenicity assay (bacterial reverse mutation), *in vitro* mouse lymphoma tk assays and *in vivo* rat bone marrow micronucleus assays.

Metformin hydrochloride

There was no evidence of a mutagenic potential of metformin in the following *in vitro* tests: Ames test (*Salmonella typhimurium*), gene mutation test (mouse lymphoma cells), or chromosomal aberrations test (human lymphocytes). Results in the *in vivo* mouse micronucleus test were also negative.

Carcinogenicity

Empagliflozin

Two-year oral carcinogenicity studies were conducted in mice and rats. There was an increase in renal adenomas and carcinomas in male mice given empagliflozin at 1000 mg/kg/day. No renal tumours were seen at 300 mg/kg/day (11- and 28-times the exposure at the clinical dose of 12.5 and 5 mg twice daily, respectively). These tumours are likely associated with a metabolic pathway not present in humans, and are considered to be irrelevant to patients given clinical doses of empagliflozin. No drug-related tumours were seen in female mice or female rats at doses up to 1000 and 700 mg/kg/day, respectively, resulting in exposures at least 60 times that expected at the clinical dose of 5 or 12.5 mg empagliflozin twice daily. In male rats, treatment-related benign vascular proliferative lesions (haemangiomas) of the mesenteric lymph node, were observed at 700 mg/kg/day, but not at 300 mg/kg/day (approximately 26- and 65-times the exposure at the clinical dose of 12.5 mg and 5 mg twice daily, respectively). These tumours are common in rats and are unlikely to be relevant to humans.

Metformin hydrochloride

Long-term carcinogenicity studies have been performed in rats (dosing duration of 104 weeks) and mice (dosing duration of 91 weeks) at doses up to and including 900 mg/kg/day and 1500 mg/kg/day, respectively. These doses are both approximately 4 times the maximum recommended human daily dose of 2000 mg based on body surface area comparisons. No evidence of carcinogenicity with metformin was found in either male or female mice. Similarly, there was no tumorigenic potential observed with metformin in male rats. There was, however, an increased incidence of benign stromal uterine polyps in female rats treated with 900 mg/kg/day.

6 PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

Each film-coated tablet of JARDIAMET contains the following inactive ingredients: copovidone, maize starch, colloidal anhydrous silica, magnesium stearate, hypromellose, titanium dioxide, macrogol 400, purified talc, iron oxide yellow (JARDIAMET 5 mg/500 mg, JARDIAMET 5 mg/850 mg, JARDIAMET 5 mg/1000 mg), iron oxide black (JARDIAMET 12.5 mg/500 mg, JARDIAMET 12.5 mg/850 mg, JARDIAMET 12.5 mg/1000 mg), iron oxide red (JARDIAMET 12.5 mg/500 mg, JARDIAMET 12.5 mg/850 mg, JARDIAMET 12.5 mg/1000 mg).

6.2 INCOMPATIBILITIES

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 SHELF LIFE

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store below 30°C.

6.5 NATURE AND CONTENTS OF CONTAINER

JARDIAMET is available in PVC/PCTFE (Aclar) / Aluminium blister packs containing 14 or 60 film-coated tablets.

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

6.7 PHYSICOCHEMICAL PROPERTIES

Empagliflozin is a white to yellowish powder. It is very slightly soluble in water, slightly soluble in acetonitrile and ethanol, sparingly soluble in methanol and practically insoluble in toluene. Empagliflozin is not hygroscopic and no polymorphism has been observed. It is neither a hydrate nor a solvate. Partition coefficient: $\log P = \log D$ (pH 7.4): 1.7.

Metformin hydrochloride is a white to off-white crystalline compound. Metformin hydrochloride is freely soluble in water and is practically insoluble in acetone, ether, and chloroform. The

pKa of metformin is 12.4. The pH of a 1% aqueous solution of metformin hydrochloride is 6.68.

Chemical structure

JARDIAMET contains two oral antihyperglycaemic drugs used in the management of type 2 diabetes mellitus: empagliflozin (a SGLT2 inhibitor) and metformin hydrochloride.


Empagliflozin

Chemical name: (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol

Molecular formula: $C_{23}H_{27}ClO_7$

Molecular weight: 450.91

Structural formula:




Metformin hydrochloride

Chemical name: 1,1-dimethylbiguanide hydrochloride

Molecular formula: $C_4H_{11}N_5 \cdot HCl$

Molecular weight: 165.63

Structural formula:



CAS number

Empagliflozin: 864070-44-0

Metformin hydrochloride: 1115-70-4

7 MEDICINE SCHEDULE (POISONS STANDARD)

S4 – Prescription Only Medicine

8 SPONSOR

Boehringer Ingelheim Pty Limited
ABN 52 000 452 308
78 Waterloo Road
North Ryde NSW 2113
www.boehringer-ingelheim.com.au

9 DATE OF FIRST APPROVAL

24 July 2015

10 DATE OF REVISION

22 February 2019

SUMMARY TABLE OF CHANGES

Section Changed	Summary of new information
4.4	Update subsection Fournier's gangrene